



10530542
PCT/EP03/11382
Rec'd 01/PTO 07 APR 2005
08 NOV 2003
INVESTOR IN PEOPLE
#2

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 21 NOV 2003

WIPO PCT


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 15 October 2003

BEST AVAILABLE COPY

* 15 OCT 2002

1977

16 OCT 02 E755994
P01/7700 0-00 0223984.6

9.4.6

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

15 OCT 2002

The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ


1. Your reference 1-32724P1/FMI

2. Patent application numl 0223984.6 16 OCT 02 E755994-1 D00524
(The Patent Office will fill in: P01/7700 0-00 0223984.63. Full name, address and postcode of the NOVARTIS FORSCHUNGSSTIFTUNG
or of each applicant ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER
(underline all surnames) INSTITUTE FOR BIOMEDICAL RESEARCH
MAULBEERSTRASSE 66, CH-4058 BASEL
SWITZERLANDPatent ADP number *(if you know it)*If the applicant is a corporate body,
give the country/state of its incorporation

SWITZERLAND

8206583001

4. Title of invention Methods for detecting teneurin signalling and related screening methods



~~B.A. YORKE & CO.
CHARTERED PATENT AGENTS
COOMB HOUSE, 7 ST. JOHN'S ROAD
ISLEWORTH
MIDDLESEX TW7 6NH~~

1800001

6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and <i>(if you know it)</i> the or each application number	Country	Priority application number <i>(if you know it)</i>	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application		Number of earlier application	Date of filing (day/month/year)

8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? <i>(Answer 'Yes' if:</i>	Yes
	a) any applicant named in part 3 is not an inventor, or	

- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

(see note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 63 ✓ W

Claim(s) 4 ✓

Abstract 1 ✓

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

One ✓

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

B. A. Yorke & Co.

15 October 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. E. Cheetham
020 8560 5847

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay please contact the Patent Office.

Case 1-32724P1/FMI

METHODS FOR DETECTING TENEURIN SIGNALLING AND RELATED SCREENING METHODS

5 Field of the invention

The present invention relates to methods of detecting teneurin signalling and methods for screening agents effective in modulating teneurin signalling with applications in the fields of neurobiology and oncology. In particular, agents affecting teneurin signalling may be 10 useful as anti-tumour and/or anti-tumourigenic agents, or for modulating neuronal differentiation, development or regeneration.

Background of the invention

15 Teneurins are a family of type II transmembrane proteins originally discovered in Drosophila. The first member was Ten-a (Baumgartner and Chiquet-Ehrismann (1993) Mech Dev 40: 165-76; Minet and Chiquet-Ehrismann (2000) Gene 257: 87-97), which was found in a search for Drosophila homologues of tenascins and shares with this protein family the same type of EGF-like repeats. The second member of the teneurin 20 family, Drosophila Ten-m/Odd oz (Odz; Baumgartner et al. (1994) Embo J 13: 3728-40) is expressed in seven stripes during the blastoderm stage of early embryos. Mutational analysis showed that ten-m/odz is a member of the "pair-rule" gene family and encodes for an extracellular protein having a central role in determining the segmentation of the embryo. The expression pattern in the developing embryos and the adult fly suggest 25 further important activities of this protein in later developmental processes since its presence often coincides with locations of morphogenetic cell movements, in particular, during gastrulation, the development of the tracheal system, on pioneering axons and in the developing eye (Baumgartner et al. (1994) Embo J 13: 3728-40); (Levine et al. (1994) Cell 77: 587-98); (Levine et al. (1997) Dev Dyn 209: 1-14).
30 Vertebrates contain four ten-a/ten-m homologues, termed ten-m1-4 (Oohashi et al. (1999) J Cell Biol 145: 563-77), odz1-4 (Ben-Zur et al. (2000) Dev Biol 217: 107-20), or teneurin 1-4 (Minet and Chiquet-Ehrismann (2000) Gene 257: 87-97), respectively. A recent study presented two new members of this family of proteins in chicken, namely, 35 teneurin-1 and teneurin-2. Both the Drosophila and chicken proteins are expressed in early stages of embryonic development, in particular, in the developing nervous system and suggest an interaction of teneurin-2 with the cytoskeleton. Expression of

recombinant teneurin-2 in a neuroblastoma cell line appears to lead to filopodia formation and enlarged growth cones (Rubin et al. (1999) *Dev Biol* 216: 195-209).

Mouse DOC4, the first vertebrate member of the teneurin family, was identified in a screen for proteins that were expressed in response to perturbation of protein folding in the endoplasmic reticulum (Wang et al. (1998) *Embo J* 17, 3619-30). Mouse DOC4 and all other vertebrate teneurins identified – namely, the mouse teneurins ten-m1-4/odz1-4 (Oohashi et al. (1999) *J Cell Biol* 145: 563-7);(Ben-Zur et al. (2000) *Dev Biol* 217: 107-20), the rat teneurin-2 orthologue, neurestin (Otaki and Firestein (1999) *Dev Biol* 212: 165-81), the chicken teneurins-1, -2 and -4 (Minet et al. (1999) *J Cell Sci* 112: 2019-32); (Rubin et al. (1999) *Dev Biol* 216: 195-209); (Tucker et al. (2000) *Mech Dev* 98, 187-91); (Tucker et al. (2001) *Dev Dyn* 220: 27-39) and the zebrafish Ten-m3 and Ten-m4 (Mieda et al. (1999) *Mech Dev* 87, 223-7) - were found to be prominently expressed in specific regions of the central nervous system.

Except for transcript localization by *in situ* hybridization in the nervous system and the possible involvement of teneurin-2 in the organization of the actin cytoskeleton in neuroblastoma cells, very little is known about the distribution and function of teneurins. Teneurins are known to be transmembrane proteins and are postulated to be involved in signal transduction. It has been suggested that teneurins could function as receptor proteins transmitting signals to the cell interior upon homo- or heterophilic binding of a ligand or as a membrane-bound ligand. Teneurin-2 is thought to be cleaved at the cell membrane either releasing a large part of the extracellular domain from the cell membrane, which could act as a soluble ligand or cleavage could occur after ligand binding and result in signal transduction (Rubin et al., *Developmental Biology*, 216, 195-209, 1999).

One potential scenario by which transmembrane proteins can fulfil their role as signalling molecules is by a mechanism recently described as regulated intramembrane proteolysis (RIP; reviewed in Brown et al. (2000) *Cell* 100, 391-98). RIP involves at least two cleavage steps in and at the membrane resulting in a soluble cytoplasmic part, which is translocated to the nucleus where it participates in transcription (Ebinu and Yankner (2002) *Neuron* 34(4):499-502. RIP is known to control diverse cellular and developmental processes. It is well known, however, that transmembrane proteins can initiate signal transduction by alternative mechanisms, such as ligand binding, receptor binding, and signalling through kinase/phosphatase cascades, etc. Indeed, *Drosophila* ten-m was postulated to modulate the activity of the *Drosophila* pair-rule gene, Odd-paired (*opa*)

protein via a signal transduction cascade (Baumgartner et al., 1994, EMBO J. 13: 3728-3740). Furthermore, the extracellular domain of mouse Ten m1 was found to exhibit homophilic binding and thereby initiate a signal transduction pathway (Oohashi et al., 1999).

- 5 Zic genes (Zic1-4) encode zinc finger proteins homologous to opa, and are expressed in both the developing and mature CNS. In vertebrate neural development, they are generally expressed in the dorsal neural tube. A similar zinc finger gene, Opr, has also been described in mice (Furushima et al. (2000) Mech. of Development 98, 161-64). Zic1
10 controls the expansion of neuronal precursors by inhibiting the progression of neuronal differentiation. Notch-mediated inhibition of neuronal differentiation is likely to act downstream of Zic genes since Notch1 is upregulated in Zic1-overexpressing spinal cords in both the mouse and the chick (Aruga et al. (2002) Dev Biol. 244(2):329-41). Reduced expression of Zic2 in mice results in spina bifida and holoprosencephaly. The
15 disruption of Zic1, a strong homolog of Zic2 that has an overlapping expression pattern, results in cerebellar malformation. It has been shown that Zic2 and Zic1 cooperatively control cerebellar development by regulating neuronal differentiation (Aruga et al. (2002) J Neurosci 22(1):218-25).
- 20 The ponsin (also known as SH3P12, CAP or FLAF2) gene encodes a protein belonging to the Ponsin/ArgBP2/venexin family. All members of this family contain three SH3 (src homology 3 region) domains. It is through these SH3 domains that Ponsin protein interacts with Vinculin, an F-actin binding protein, at cell-cell and cell-matrix adherens junctions or with Afadin at Zonula adherens (Mandai et al. (1999) J. Cell Biol. 144: 1001-1017). Ponsin also directly interacts with the non-receptor focal adhesion tyrosine kinase p125 FAK (Ribon et al. (1998a) J. Biol. Chem. 273: 4073-4080). Several splice variants of Ponsin mRNA exist, which are specifically up-regulated by p53 expression in EB-1 cells and by adriamycin treatment of TK6 cells (Kostic et al. (2000) Oncogene 19(35):3978-87). Loss of wild type p53 function in colon tumours coincide with migration
25 of the tumour mass across the basement membrane.

- 30 PML (a protein named for its prevalence in promyelocytic leukemia) is a nuclear protein that controls apoptosis, cell proliferation and senescence and it is believed to be a zinc finger transcription factor. The PML gene, involved in the chromosomal translocation of acute promyelocytic leukemia (APL), encodes a protein which is located in nuclear
35 substructures called PML-bodies and which plays a role in tumour suppression (reviewed

in Seeler et al. (1999) Curr Opin Genet Dev. 9(3):362-7; or Salomoni and Pandolfi (2002) Cell 108, 165-70).

A need exists to find signalling pathways and genes that are involved in the development
 5 of neuropathological, neurodevelopmental, and neurodegenerative diseases or conditions as well as in other therapeutic areas, such as cancer, to more accurately and effectively diagnose and treat these diseases. A more complete delineation of the teneurin signalling pathway and identification of the pathway's components provided by the present invention meets this need.

10

Summary of the invention

In accordance with a first aspect of the invention a method for detecting teneurin signalling is provided, which method comprises providing (i) a teneurin or a fragment thereof, which fragment comprises at least a portion of the N-terminal domain of teneurin and at least a portion of the C-terminal domain of teneurin, and (ii) a cellular component that cleaves the teneurin; determining the presence and/or amount of a cleaved teneurin product associated with the signalling; and correlating the presence and/or amount of the cleaved teneurin product with teneurin signalling. The cleaved teneurin product
 15 comprising the cytoplasmic domain of teneurin or a fragment thereof and may be present without limitation in tumour cells containing PML nuclear bodies or in neurons. In one embodiment teneurin is teneurin-1, in another embodiment it is teneurin-2, teneurin-3, or teneurin-4.

20
 25 The method of the invention for detecting teneurin signalling further comprises labelling teneurin with a detectable tag or label. In one aspect, the labelled teneurin is recombinant. In another embodiment of the present invention, the cleaved teneurin product comprises a detectable tag or label. Said tag or label may be detected photometrically and may be without limitation GFP (green fluorescence protein) or YFP (yellow fluorescence protein).
 30

In one aspect, the determination of the presence and/or amount of a cleaved teneurin product associated with the signalling is qualitative.

35
 35 In a further embodiment, a method is provided further comprising expressing tagged teneurin from nucleic acid encoding therefor introduced into a cell or a progenitor thereof, wherein said tag may comprise a DNA binding domain which binds to nucleic acid

comprising regulatory sequences operably linked to a reporter gene. Said DNA binding domain comprises without limitation GAL 4 DNA binding domain. In another embodiment, said tag further comprises a NF κ B domain. The present invention further comprises nucleic acid encoding for tagged teneurin which is stably expressed in a cell, e.g. a

5 tumour cell or a neuron.

In a further aspect, the present invention provides a method for detecting teneurin signalling wherein the cleaved teneurin product regulates expression or activity of a cellular target which itself is a modulator of cell proliferation or neuronal differentiation,

10 e.g. PML, Zic, ponsin, p53 and myc, or wherein the cleaved teneurin product targets to the nucleus. Said cellular target of the cleaved teneurin product may be detected by expression array analysis.

Also provided is a method for detecting teneurin signalling wherein the presence and/or amount of the detectable cleaved teneurin product is correlated to a particular disease.

15 This method can be performed for determining whether a cleaved teneurin product is involved in cell proliferation or neuronal differentiation.

In one embodiment, an *in vitro* method of diagnosis of a neuropathology or cell pathology which affects teneurin-mediated signalling is provided which comprises performing the hereinabove described methods of the invention on a cell which has been extracted from

20 an animal which it is desired to diagnose.

In another embodiment, the use of a detectable cleaved teneurin product associated with teneurin signalling in an *in vivo* method of diagnosis of a neuropathology or cell pathology which affects teneurin signalling is provided, which method comprises performing a

25 method of the invention as hereinabove described.

The invention further provides a method for assessing the ability of an agent to modulate teneurin signalling, comprising the steps of: (a) contacting teneurin with at least one agent in the presence of a cellular component; (b) detecting cleavage of said teneurin in the presence or absence of said agents by use of a method of the invention; and (c)

30 correlating the value obtained in step (b) with a value obtained in the absence of said agent, and correlating a difference between values as an indication of the presence of an

35 agent effective in modulating teneurin signalling.

In another aspect, a method for assessing the ability of an agent to modulate teneurin signalling is provided further comprising: (a) determining the presence and/or amount of cleaved teneurin product in a cell; (b) exposing the cell expressing teneurin to the agent; (c) measuring the presence and/or amount of cleaved teneurin product in the presence of
5 the agent; and (d) comparing the determinations made in (a) and (c). Also provided is a method wherein step (b) is performed by perfusing the cell with the agent.

In another aspect, a method for assessing the ability of an agent to modulate teneurin-mediated signalling is provided, comprising the steps of: (a) measuring expression or
10 activity of genes regulated by teneurin in cells; (b) exposing said cells to the agent; (c) measuring expression or activity of genes regulated by teneurin in said cells in the presence of the agent; and (d) correlating a modulated value in step (a) compared to step (c) with the ability of the agent to regulate teneurin signalling.

15 Also provided is a method of screening for compounds for the potential to modulate cell proliferation or for compounds for the treatment of neurodegenerative disease or disorder or for the treatment of cancer, which method comprises assessing the ability of said compounds to modulate teneurin signalling by use of a method of the invention. In another embodiment, a method of screening is provided further comprising the
20 subsequent step of isolation and/or manufacture and/or use in a method of treatment, of an agent which tests positive.

In a further aspect, a composition detected by a method of screening of the invention is provided for the treatment or prophylactic treatment of tumourigenesis or cancer or for
25 the treatment or prophylactic treatment of neuropathology. The composition detected by a method of screening can be used for the manufacture of a medicament for the treatment or prophylactic treatment of tumourigenesis or cancer or for the manufacture of a medicament for the treatment or prophylactic treatment of neuropathology.

30 Also provided is the use of a cleaved teneurin product for the manufacture of a medicament for the treatment or prophylactic treatment of tumourigenesis or cancer or neuropathology.

35 Further provided is a composition comprising a cleaved teneurin product and a cellular target of the cleaved teneurin product, such as PML, Zic, p53, myc or ponsin.

Detailed description of the invention

- Intracellular pathways are known to be regulated by a cascade of components that undergo modulation in a temporally and spatially characteristic manner. Several disease states can be attributed to altered activity of individual signalling components (e.g., protein kinases, protein phosphatases and transcription factors). These components therefore render themselves as attractive targets for therapeutic intervention, or as targets for agents that seek to obtain a biological effect by modulating a signalling pathway. Typically, modulation of a signalling pathway will alter the response of a cell to a particular stimulus in a variety of ways. Although much work has been carried out in attempting to delineate the involvement of proteins in signalling pathways, prior to the present invention no hypothesis was put forward linking teneurin to components of a signalling pathway.
- The present inventors have demonstrated for the first time that teneurin is involved in intracellular signalling by its cytoplasmic domain interacting with cellular targets that influence gene transcription and are involved in cerebellar development, neuronal differentiation, apoptosis, cell proliferation and senescence. Modulation of teneurin signalling to these targets may therefore have application in neuropsychiatric, neurodevelopmental, and neurodegenerative diseases and other CNS diseases or conditions, as well as for the understanding of neuronal differentiation, cell proliferation and oncogenesis.
- The present inventors have found that teneurin is involved in intracellular signalling and exhibits transcriptional activity through its cytoplasmic domain. The cytoplasmic domain of teneurin-2 can be released from the cell membrane and translocates to the cell nucleus where it is able to influence the transcription activity of various target genes including zic-1, a vertebrate homologue of the *Drosophila* opa. Teneurin signalling may be of importance in many neurodevelopmental and neurodegenerative diseases and disorders, such as schizophrenia, Alzheimer's, Parkinsons disease, amyloid angiopathies, and other developmental disorders such as spina bifida and mental retardation. In addition teneurin is thought to be important in adhesion, signalling, regulating cell survival, proliferation and differentiation and teneurin signalling may have applications in cell proliferation, such as in cancer.
- Zic1, is a zinc finger transcription factor homologous to the *Drosophila* pair-rule gene opa, a possible downstream target of one of the *Drosophila* teneurins.

The present inventors have investigated the role of teneurin in intracellular signalling and found intracellular teneurin targets. Using live imaging of cells expressing labelled or tagged proteins, the inventors showed that transfection of cells with a construct

5 expressing the cytoplasmic domain of teneurin-2 resulted in the translocation of the cytoplasmic domain to the nucleus of the cells. Its expression was confined to discrete spots within the nucleus in contrast to the staining pattern of teneurin comprising the transmembrane domain of teneurin-2, which showed accumulation on the cell surface (Example 1). The nuclear localisation coincided with a very similar punctate pattern
10 obtained by staining for PML (promyelocytic leukemia), a protein which localizes to the PML-nuclear bodies and which controls apoptosis, cell proliferation, and senescence. An identical staining pattern was detected after co-transfection of the cytoplasmic domain of teneurin-2 with PML, suggesting an involvement of the cytoplasmic domain of teneurin-2 in transcriptional regulation.

15 Furthermore, the present inventors have demonstrated that co-transfection of the cytoplasmic domain of teneurin-2 with Zic1 reduced the transcriptional activity of Zic which suggests a role of teneurin in the control of cerebellar development by regulating neuronal differentiation and other neurological conditions.

20 In a yeast-two-hybrid screen the cytoplasmic domain of teneurin-1 was found to bind to ponsin, a p53 responsive gene also involved in apoptosis and senescence. The present inventors confirmed this binding by co-transfection and co-immunoprecipitation of the two proteins.

25 Microarray analysis was performed using Affymetrix HG-U133A GeneChips™ to identify genes that are regulated by teneurin signalling. Among the genes up- and down-regulated by teneurin-2, many were shown to play a role in the regulation of cell growth, differentiation and apoptosis. A group of genes down-regulated by teneurin-2 correlated
30 with genes known to be glutathionylated and involved in the regulation of the redox status of cells. Many of the teneurin-2 up-regulated genes are targets of p53, whereas many of the teneurin-2 down-regulated genes are targets of myc.

Together these data indicate that teneurin plays a role in intracellular signalling pathways
35 which has not been known from previous studies. In general terms, the present invention relates to a cleaved teneurin product as a specific 'marker' for teneurin-mediated signalling.

- Accordingly, a method for detecting teneurin signalling is provided, which method comprises (a) determining the presence and/or amount of a cleaved teneurin product associated with the signalling; and (b) correlating the presence and/or amount of the 5 cleaved teneurin product with teneurin signalling. Optionally, the method further comprises providing a teneurin or a fragment thereof comprising at least a portion of the N-terminal domain of teneurin and at least a portion of the C-terminal domain of teneurin, and a cellular component that cleaves teneurin.
- 10 By 'signalling' is meant a process regulated by a cascade of components that undergoes modulation in a temporally and spatially characteristic manner (Gomperts et al., (2002), Signal transduction, San Diego, Academic Press, 424 p.; or Krauss (2001), Biochemistry of Signal Transduction and Regulation, Wiley-VCH, 2nd edition, 528 p.). Activity of individual intracellular signalling components (e.g., protein kinases, protein 15 phosphatases, transcription factors) can be altered in several disease states. Teneurin signalling can be detected by analysing the modulation (up- or down-regulation) of downstream targets of teneurin, which play a role in the regulation of cell growth, differentiation and apoptosis.
- 20 The teneurin protein provided for the method of the present invention may be mammalian teneurin, preferably mouse or rat teneurin, more preferably human teneurin. It may be chosen from teneurin-1, teneurin-2, teneurin-3 or teneurin-4 (described in Minet and Chiquet-Ehrismann (2000) *Gene* 257: 87-97).
- 25 By a 'fragment' of teneurin is meant a fragment comprising a protease cleavage site and at least a portion of the exodomain of teneurin, a transmembrane domain, and at least a portion of the cytoplasmic domain of teneurin. The portion will typically be at least one, preferably at least ten or more amino acid residues in length.
- 30 A 'cellular component' in the meaning of the present invention has a protease activity and is capable of cleaving teneurin to provide a fragment capable of signalling and affecting teneurin targets. The activity may regulate intramembrane proteolysis (RIP), where at least two cleavage steps by proteases lead to the separation of the intracellular part from the membrane. The first cleavage and splitting off of the truncated extracellular or 35 intraluminal parts are prerequisite for the second cleavage. The latter takes place within the transmembrane domain. The resulting soluble cytoplasmic part is subsequently translocated to the nucleus where it participates in transcription (reviewed in Brown et al.

- (2000) Cell 100, 391-98). The cellular component of the present invention may thus work in conjunction with another protease activity, but comprises at least one protease capable of cleaving teneurin in or at the transmembrane domain resulting in a soluble cleaved teneurin product associated with teneurin signalling. The protease may be selected from
- 5 the group including, without limitation, site 1 proteases, site 2 proteases, or alpha-, beta- or gamma-secretase. These proteases have been shown to be involved in the regulated intramembrane proteolysis (RIP) mediated nuclear signalling (Ebinu and Yankner (2002) Neuron 34(4):499-502).
- 10 The cleaved teneurin product of the invention comprises the cytoplasmic domain of teneurin or a fragment thereof and may be present, without limitation, in tumour cells containing PML nuclear bodies or in neurons. The cytoplasmic domain of teneurin may be a polypeptide having the amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8, or a variant thereof such as a variant comprising an
- 15 amino acid deletion, addition (e.g. fusion proteins) or substitution relative to the above mentioned amino acid sequences. The various nucleic acids that can encode these polypeptides therefore may differ because of the degeneracy of the genetic code, in that most amino acids are encoded by more than one triplet codon. The identity of such codons is well known in this art, and this information can be used for the construction of
- 20 the nucleic acids within the scope of the invention. Variants differ from wild-type protein in having one or more amino acid substitutions that enhance, add, or diminish a biological activity of the wild-type protein.
- 25 By a 'fragment of the cytoplasmic domain of teneurin' is meant a fragment of a polypeptide having a number of amino acid residues in the range of 5-400, more preferably 10-300, most preferably 20-200.
- Exemplary functional equivalents or derivatives of the amino acid sequences shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8 include molecules
- 30 wherein the polypeptide of the invention is covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid. Derivatives which retain common structural features can be fragments of the protein of the invention, in particular fragments maintaining teneurin signalling activity. Useful fragments may exhibit an epitope recognized by polyclonal or monoclonal
- 35 antibodies raised against the polypeptide having the amino acid sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8 for example. Particularly

preferred fragments are those exhibiting a sequence capable of inducing or inhibiting teneurin signalling.

- The determination step in the method may be preceded by exposing the cell or the cell
5 free system to ponasterone or to another putative or known activating stimulus, including without limitation pharmacological agents, to induce expression of teneurin.

In some embodiments, the method for detecting teneurin signalling further comprises labelling teneurin or the cleaved teneurin product with a detectable tag or label. In one
10 aspect, the labelled teneurin is recombinant, such as in the form of a fusion with another protein, for example, tags for the targeted delivery or detection of the polypeptide (including fragments thereof). It is desirable that the tag or label is easily detectable. In principle it may be inherently detectable (e.g. a protein identifiable by a consonant antibody). Immunological methods of detection include, Western blot,
15 immunohistochemical staining of cells or tissue sections, and assays of cell culture, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared by conventional methods well known in the art. Conveniently, the antibodies may be prepared against a native sequence of the tag or
20 label.

- In preferred embodiments the 'label' in the meaning of the present invention will include a specific detectable label for increased ease of scoring and/or sensitivity. Most preferably the activity of the labelled protein, or the protein itself, can be estimated photometrically
25 (especially by fluorimetry or luminometry). This may be directly e.g. using for instance green fluorescent protein (GFP), yellow fluorescent protein (YFP), insect luciferase or photobacterial luciferase. Alternatively, a radioactive or phosphorescent label may be used.
30 In another preferred embodiment, a 'tag' may be used wherein the detection may be indirect e.g. whereby the signal gene causes a change which is detected by a colour indicator e.g. on staining. Other suitable signal proteins (which have a readily detectable activity) are known in the art e.g. β -galactosidase, which can generate a coloured product from its substrate. The signal may utilise co-factors. The tag may alternatively comprise a
35 DNA binding domain which binds to nucleic acid comprising regulatory sequences operably linked to a reporter gene. The DNA binding domain may be, for example and

without limitation, the GAL 4 DNA binding domain. In another embodiment, the tag may further comprise an NF κ B domain.

The method thus encompasses the detection of teneurin signalling by means of a
5 cleaved teneurin product which is associated with the signalling and a detectable tag or label in that the presence and/or amount of the cleaved teneurin product is increased when teneurin signalling is activated. In general the tag or label under the conditions used in the method, will not be present (or detectably present) prior to contacting the cell or the cell free system with another cellular component, a protease. The determination of
10 the presence and/or amount of the detectable tag or label attached to the cleaved teneurin product may be either qualitative or quantitative, and the correlation may be based on comparison with the tag or label in unactivated systems (either directly, or based on historical or contemporaneous comparison). For instance the amount of detectable cleaved teneurin product may be scored in each case and the scores
15 compared.

In order to produce suitable test systems including detectable cleaved teneurin product, it will generally be preferred to use nucleic acid encoding teneurin, which is either stably or transiently expressed. A nucleic acid encoding teneurin or its labelled or tagged variants
20 may therefore be introduced into a cell or a progenitor thereof to obtain expression of the protein. Preferably, the teneurin is stably expressed in a cell. Alternatively, cells expressing teneurin can be used, such as tumour cells, neurons or a progenitors thereof. In a preferred embodiment, cultured tumour cells are used. Alternatively, the teneurin may be employed by in a cell free system and allowing detection with an antibody or
25 using protein-protein interactions, for example.

Nucleic acids of, or for use in, the present invention (e.g. encoding labelled teneurin) may be provided isolated from their natural environment, in substantially pure or homogeneous form, or free or substantially free of other nucleic acids of the species of origin. Where used herein, the term "isolated" encompasses all of these possibilities.
30 Nucleic acid according to the present invention may be in the form of, or derived from, cDNA, RNA, genomic DNA and modified nucleic acids or nucleic acid analogs. Thus the invention also relates, in a further aspect, to use of a nucleic acid molecule which comprises a nucleotide sequence encoding teneurin described above linked to a
35 detectable label, in the various methods of the invention.

- Nucleic acid sequences which encode a tagged polypeptide or peptide linked to a label in accordance with the present invention can be readily prepared by the skilled person using the information and references contained herein and techniques known in the art (for example, see Sambrook, Fritsch and Maniatis, "Molecular Cloning, A Laboratory Manual", Cold Spring Harbor Laboratory Press, 1989, and Ausubel et al., Short Protocols in Molecular Biology, John Wiley and Sons, 1992). These techniques include (i) the use of the polymerase chain reaction (PCR) to amplify samples of the relevant nucleic acid, e.g. from genomic sources, (ii) chemical synthesis, or (iii) preparation of cDNA sequences.
- Thus in cell-based assays of the present invention, the labelled protein of interest can be introduced by causing or allowing the expression in a cell of an expression construct or vector. The construct may include any other regulatory sequences or structural elements as would commonly be included in such a system, and as is described below. As well as the signal sequence, the vector components will usually include, but are not limited to, one or more of an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.
- Nucleic acid sequences which enable a vector to replicate in one or more selected host cells are well known for a variety of bacteria, yeast, and viruses. For Example, various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Particularly preferred is an expression vector comprising a nucleic acid as described herein. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, phage, or any other suitable vector or construct which can be taken up by a cell and used to express the detectable marker.
- Expression vectors usually contain a promoter operably linked to the protein-encoding nucleic acid sequence of interest, so as to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. "Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional control" of the promoter. Transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian

Virus 40 (SV40), from heterologous mammalian promoters, e.g. the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

- 5 Expression vectors of the invention may also contain one or more selection genes. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins e.g. ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

10 The method of the invention may therefore further include introducing the nucleic acid into a host cell. The introduction, which may (particularly for *in vitro* introduction) be generally referred to without limitation as "transformation", may employ any available technique. For eukaryotic cells, suitable techniques may include calcium phosphate
15 transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g. vaccinia or, for insect cells, baculovirus. For example, the calcium phosphate precipitation method of Graham and van der Eb, Virology 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transformations have been described in U.S. Patent No. 4,399,216. For various
20 techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature 336:348-352 (1988).

- Host cells transfected or transformed with expression or cloning vectors described herein may be cultured in conventional nutrient media. The culture conditions, such as media,
25 temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in "Mammalian Cell Biotechnology: a Practical Approach", M. Butler, ed. JRL Press, (1991) and Sambrook et al, *supra*.
- 30 There is no requirement that labelled teneurin of the present invention has to include the full-length sequence of the protein as it occurs in nature. Variants may be used (e.g. which are derived from teneurin) which retain its activity. The term "derived" includes variants produced by modification of the authentic native sequence e.g. by introducing changes into the full-length or truncated sequence, for example substitutions, insertions,
35 and/or deletions. This may be achieved by any appropriate technique, including restriction of the coding sequence with an endonuclease followed by the insertion of a selected base sequence (using linkers if required) and ligation. Also possible is

PCR-mediated mutagenesis using mutant primers. It may, for instance, be preferable to add in or remove restriction sites in order to facilitate further cloning.

Modified sequences according to the present invention may have a sequence at least 5 60% identical to the sequence of teneurin. Typically there would be 80% or more, 90% or more 95% or more or 98% or more identity between the modified sequence and the authentic sequence. There may be up to five, for example up to ten or up to twenty or more nucleotide or amino acid deletions, insertions and/or substitutions made to the full-length or part length sequence provided functionality is not totally lost. Similarity or 10 identity may be as defined and determined by the TBLASTN program, of Altschul et al. (1990) *J. Mol. Biol.* 215: 403-10, or BestFit, which is part of the Wisconsin Package, Version 8, September 1994, (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA, Wisconsin 53711). Preferably sequence comparisons are made using FASTA and FASTP (see Pearson & Lipman, 1988. *Methods in Enzymology* 183: 63-98). 15 Parameters are preferably set, using the default matrix, as follows: Gapopen (penalty for the first residue in a gap): -16 for DNA; Gapext (penalty for additional residues in a gap): -4 for DNA KTUP word length: 6 for DNA. Alternatively, homology in the context of nucleic acids can be judged by probing under appropriate stringency conditions. One common formula for calculating the stringency conditions required to achieve 20 hybridization between nucleic acid molecules of a specified sequence homology is (Sambrook et al., 1989): $T_m = 81.5^\circ\text{C} + 16.6\log [\text{Na}^+] + 0.41 (\% \text{ G+C}) - 0.63 (\% \text{ formamide}) - 600/\# \text{bp}$ in duplex.

The present inventors have demonstrated for the first time that the cytoplasmic domain of 25 teneurin, the cleaved teneurin product of the invention, contains transcriptional activity or acts as a transcriptional modulator which are characteristics of proteins regulated by RIP (regulated intramembrane proteolysis). It could be found that the cytoplasmic domain of teneurin translocates to the nucleus and is capable of interacting with a cellular target. These targets are found to include without limitation proteins belonging to the 30 ponsin/ArgBP2/venexin family (including without limitation ponsin, SH3P12, CAP, SORB1, ArgBP2, venexin, nArgBP2, FLAF2), preferably ponsin (see Example 3), nuclear targets such as the nuclear protein PML (promyelocytic leukemia, see Example 1), or transcription factors such as zinc finger proteins which include without limitation Zic1-4, or Opr, preferably Zic1 (see Example 2), as well as other targets that are involved in 35 neuronal differentiation or cell proliferation detected by expression array analysis (Example 5, Table 1 and 2) which might include without limitation neuroserpin, protein kinase C (PKC) or any other hitherto unknown target of teneurin. Signalling

In a further aspect, the present invention provides compositions capable of enhancing or inhibiting expression or activity of the cellular targets that regulate cell proliferation or neuronal differentiation. Therefore, depending on the function of its intracellular target,

- 5 the cleaved teneurin product of the present invention is indirectly capable of enhancing or inhibiting transcriptional activation.

In a further aspect, the present invention provides a method for detecting teneurin signalling wherein the cleaved teneurin product regulates expression or activity of a

- 10 cellular target which itself is a modulator of cell proliferation or neuronal differentiation, which may include, without limitation, PML, Zic, ponsin, p53-regulated genes, myc-regulated genes, or wherein the cleaved teneurin product targets to the nucleus. The cellular target of the cleaved teneurin product may be detected by expression array analysis.

15

Also provided is a method for detecting teneurin signalling wherein the presence and/or amount of the detectable cleaved teneurin product is correlated to a particular disease. This method can be performed for determining whether a cleaved teneurin product is involved in cell proliferation or neuronal differentiation.

20

A 'disease' correlated to the cleaved teneurin product of the invention may mean any disease wherein cell proliferation or neuronal differentiation is affected, any cell pathology or neuropathology including, without limitation, neurodevelopmental and neurodegenerative diseases and disorders such as schizophrenia, multiple sclerosis,

- 25 Alzheimer's, Parkinsons disease, amyloid angiopathies, and other developmental disorders such as spina bifida or even mental retardation, as well as cancer. Targets of the cleaved teneurin product of the invention have been shown to be involved in tumourigenesis (e.g. ponsin which is up-regulated by p53 expression, described in Kostic et al. (2000) Oncogene 19(35):3978-87), in neuronal differentiation and cerebellar

- 30 development (reduced expression of Zic results in spina bifida and holoprosencephaly, described in Aruga et al. (2002) Dev Biol. 244(2):329-41), or in cell proliferation or apoptosis (PML, described in Salomoni and Pandolfi (2002) Cell 108, 165-70).

In one embodiment, an *in vitro* method of diagnosis of a neuropathology or cell pathology which affects teneurin-mediated signalling is provided which comprises performing the hereinabove described methods of the invention on a cell which has been extracted from an animal which it is desired to diagnose.

The cleaved teneurin product disclosed herein may be used as a diagnostic. The expression of the cleaved teneurin product or the expression or activity of target genes of the cleaved teneurin product may be correlated to a particular disease state (which may

5 include, without limitation, schizophrenia, Alzheimer's, Parkinson's disease, amyloid angiopathies, spina bifida, multiple sclerosis, mental retardation, or cancer) and based on the diagnosis particular therapies could be chosen. Thus the invention provides methods of diagnosis and use of the materials disclosed herein in such methods, particularly in respect of neuropathologies or cancer.

10 The invention further provides the use of a detectable cleaved teneurin product associated with teneurin signalling in an *in vivo* method of diagnosis of a neuropathology or cell pathology which affects teneurin signalling is provided, which method comprises performing a method of the invention as hereinabove described.

15 For *in vivo* methods, host cells according to the present invention (i.e. including the detectable teneurin) may be comprised in a transgenic animal, and the present invention further provides for a transgenic animal, comprising cells which express a labelled teneurin, such as a fusion protein of teneurin with a fluorescent protein, and also uses 20 thereof. The transgenic organisms of the invention all include within a plurality of their cells a cloned recombinant or synthetic DNA sequence which encodes the labelled teneurin.

25 Since it is possible to produce transgenic organisms of the invention utilizing a variety of labels and tags, a general description will be given of the production of transgenic organisms by referring generally to exogenous genetic material. This general description can be adapted by those skilled in the art in order to incorporate the above-described specific DNA sequences into organisms and obtain expression of those sequences utilizing the methods and materials described below. For more details regarding the 30 production of transgenic organisms, and specifically transgenic mice, refer to U.S. Pat. No. 4,873,191, issued Oct. 10, 1989 (incorporated herein by reference to disclose methods producing transgenic mice), and to the numerous scientific publications referred to and cited therein.

35 The exogenous genetic material may be placed in either the male or female pronucleus of the zygote. More preferably, it is placed in the male pronucleus as soon as possible after the sperm enters the egg. In other words, right after the formation of the male

pronucleus when the pronuclei are clearly defined and are well separated, each being located near the zygote membrane. The male pronucleus of a fertilized mouse egg is the preferred site for addition of the exogenous genetic material of the present invention.

- 5 It is most preferred that the exogenous genetic material be added to the male DNA complement of the zygote prior to its being processed by the ovum nucleus or the zygote female pronucleus. It is thought that the ovum nucleus or female pronucleus release molecules which affect the male DNA complement, perhaps by replacing the protamines of the male DNA with histones, thereby facilitating the combination of the female and
- 10 male DNA complements to form the diploid zygote.

- Thus, it is preferred that the exogenous genetic material be added to the male complement of DNA or any other complement of DNA prior to its being affected by the female pronucleus. For example, the exogenous genetic material is added to the early
- 15 male pronucleus, as soon as possible after the formation of the male pronucleus, which is when the male and female pronuclei are well separated and both are located close to the cell membrane. Alternatively, the exogenous genetic material could be added to the nucleus of the sperm after it has been induced to undergo decondensation. Sperm containing the exogenous genetic material could then be added to the ovum or the
- 20 decondensed sperm could be added to the ovum with the exogenous genetic material being added as soon as possible thereafter.

- For the purposes of this invention a zygote is essentially the formation of a diploid cell which is capable of developing into a complete organism. Generally, the zygote will be
- 25 comprised of an egg containing a nucleus formed, either naturally or artificially, by the fusion of two haploid nuclei from a gamete or gametes. Thus, the gamete nuclei must be ones which are naturally compatible, i.e., ones which result in a viable zygote capable of undergoing differentiation and developing into a functioning organism. Generally, a euploid zygote is preferred. If an aneuploid zygote is obtained, then the number of
- 30 chromosomes should not vary by more than one with respect to the euploid number of the organism from which either gamete originated.

- In addition to similar biological considerations, physical ones also govern the amount of exogenous genetic material which can be added to the nucleus of the zygote or to the
- 35 genetic material which forms a part of the zygote nucleus. If no genetic material is removed, then the amount of exogenous genetic material which can be added is limited by the amount which will be absorbed without being physically disruptive. Generally, the

- volume of exogenous genetic material inserted will not exceed about 10 picoliters. The physical effects of addition must not be so great as to physically destroy the viability of the zygote. The biological limit of the number and variety of DNA sequences will vary depending upon the particular zygote and functions of the exogenous genetic material
- 5 and will be readily apparent to one skilled in the art, because the genetic material, including the exogenous genetic material, of the resulting zygote must be biologically capable of initiating and maintaining the differentiation and development of the zygote into a functional organism.
- 10 The number of copies of the DNA sequences which are added to the zygote is dependent upon the total amount of exogenous genetic material added and will be the amount which enables the genetic transformation to occur. Theoretically only one copy is required; however, generally, numerous copies are utilized, for example, 1,000-20,000 copies of a gene, in order to insure that one copy is functional. As regards the present invention,
- 15 there is generally an advantage to having more than one functioning copy of each of the inserted exogenous DNA sequences to enhance the phenotypic expression of the exogenous DNA sequences.
- Any technique which allows for the addition of the exogenous genetic material into
- 20 nucleic genetic material can be utilized so long as it is not destructive to the cell, nuclear membrane or other existing cellular or genetic structures. The exogenous genetic material is preferentially inserted into the nucleic genetic material by microinjection. Microinjection of cells and cellular structures is known and is used in the art.
- 25 Thus the present invention provides methods in which cloned recombinant DNA sequences encoding appropriate membrane targeting sequences may be injected into fertilized mammalian eggs (preferably mouse eggs). The injected eggs are implanted in pseudo pregnant females and are grown to term to provide transgenic mice whose cells express proteins related to the pathology of the relevant disease. The injected sequences
- 30 are constructed having promoter sequences connected so as to express the desired protein in specific tissues of the transgenic mammal (most notably in nerve tissue). Examples may include the prion specific promoter of Lewis et al (2000) Nature Genetics 25, 402-405, or the neurospecific enolase promoter.
- 35 Non-human animals of the invention may be homozygous or heterozygous for the fusion polypeptide. Mammalian animals include non-human primates, rodents, rabbits, sheep, cattle, goats, pigs. Rodents include mice, rats, and guinea pigs.

Transgenic non-human mammals of the invention may, *inter alia*, be used for experimental purposes in studying neuronal development or cell proliferation and the development of therapies designed to alleviate the symptoms of disease in which

- 5 improper teneurin signalling is implicated. By "experimental" it is meant permissible for use in animal experimentation or testing purposes under prevailing legislation applicable to the research facility where such experimentation occurs.

An important aspect of the present invention is the use of the detectable teneurin or of

- 10 the detectable cleaved teneurin product disclosed herein to screen for modulators affecting teneurin signalling, for example modulators (e.g. agonists or antagonists) affecting transcription of genes regulated by teneurin and therefore affecting cell proliferation, apoptosis, neuronal differentiation, epilepsy, neurodegeneration, multiple sclerosis, schizophrenia, Alzheimer's, Parkinsons disease, amyloid angiopathies, and
15 other developmental disorders such as spina bifida or even mental retardation. This can be achieved in the light of the disclosure herein by looking for compounds that would enhance (for agonists) or suppress (for antagonists) expression of the cleaved teneurin product (or cause activation or redistribution of other proteins that are regulated by teneurin), or that would enhance or suppress protease activity of proteases that cleave
20 teneurin. Thus, an indicator for the cleaved teneurin product is useful for screening for compounds that improve cancerous conditions or induce neuronal regeneration.

Accordingly, the present invention provides a method for screening compounds for the potential modulation of teneurin signalling comprising assaying for a modification of

- 25 labelled cleaved teneurin product targeting to the nucleus of a cell.

Thus, the invention provides a method for assessing the ability of an agent to modulate teneurin signalling, comprising the steps of: (a) contacting teneurin with at least one agent in the presence of a cellular component; (b) detecting cleavage of said teneurin in
30 the presence or absence of said agents by use of a method of the invention as hereinabove described; and (c) correlating the value obtained in step (b) with a value obtained in the absence of said agent, and correlating a difference between values as an indication of the presence of an agent effective in modulating teneurin signalling. An increase in cleaved teneurin product correlates with an agent that is an agonist of

- 35 teneurin signalling or an agonist of a protease involved in the cleavage process of teneurin and may therefore be used as an anti-tumour agent. A decrease in cleaved teneurin product correlates with an agent that is an antagonist of teneurin signalling or an

antagonist of a protease involved in the cleavage process of teneurin and may therefore be used as an agent inhibiting neuronal degeneration.

Thus the various methods described above may comprise the further steps of contacting
5 the cleaved teneurin product, or proteases cleaving teneurin, with one or more agents which it is desired to assess for ability to modulate teneurin signalling, and comparing the signalling in the presence or absence of said agents - the relative values may be correlated with its activity as a modulator.

10 Therefore, a method for assessing the ability of an agent to modulate teneurin signalling is provided further comprising: (a) determining the presence and/or amount of cleaved teneurin product in a cell; (b) exposing the cell expressing teneurin to the agent; (c) measuring the presence and/or amount of cleaved teneurin product in the presence of the agent; and (d) comparing the determinations made in (a) and (c). Also provided is a
15 method wherein step (b) is performed by perfusing the cell with the agent.

In another aspect, a method for assessing the ability of an agent to modulate teneurin-mediated signalling is provided, comprising the steps of: (a) measuring expression or activity of genes regulated by teneurin in cells; (b) exposing said cells to the agent; (c)
20 measuring expression or activity of genes regulated by teneurin in said cells in the presence of the agent; and (d) correlating a modulated value in step (a) compared to step (c) with the ability of the agent to regulate teneurin signalling.

Also provided is a method of screening for agents for the potential to modulate cell
25 proliferation for the treatment of cancer or diabetes or for agents for the treatment of neurodegenerative disease or disorder, which method comprises assessing the ability of said agents to modulate teneurin signalling by use of a method of the invention.

Where the method of identifying modulators utilizes a cell-based system, it may further
30 include the step of testing the viability of the cells expressing the labelled cleaved teneurin product e.g. by use of a lactate dehydrogenase assay kit (Sigma). This step may provide an indication of any interference by the test agent of vital cellular functions.

Essentially, methods of the present invention may be employed analogously to high
35 throughput screens such as those well known in the art - see e.g. WO 200016231 (Navocyte); WO 200014540 (Tibotec); DE 19840545 (Jerini Biotools); WO 200012755 (Higher Council for Scientific Research); WO 200012705 (Pausch MH; Wess J); WO

200011216 (Bristol-Myers Squibb); US 6027873 (Genencor Intl.); DE 19835071 (Carl Zeiss; F Hoffman-La Roche); WO 200003805 (CombiChem); WO 200002899 (Biocept); WO 200002045 (Euroscren); US 6007690 (Aclara Biosciences).

- 5 Agents which are tested may be any which it is desired to assess for the relevant signalling.

The methods can serve either as primary screens, in order to identify new inhibitors/modulators, or as secondary screens in order to study known

- 10 inhibitors/modulators in further detail.

'Agents' may be natural or synthetic chemical compounds. Relatively small chemical compounds, preferably which are capable of crossing the blood-brain barrier, may be preferred. Inhibition of the proteases involved in the separation of the intracellular part of teneurin from the membrane part can block signalling and therefore inhibit or activate transcription. Specific protease inhibitors could therefore be particularly useful as potential agents for inhibiting teneurin signalling and could be used as potent tools to prevent generation of signalling products or as specific targets for cancer therapy.

- 20 The skilled person will appreciate that the amount of test substance or compound which is added in a screening assay according to this aspect of the invention will normally be determined by trial and error depending upon the type of compound used. It may be selected to be a level which could realistically be used in therapeutic context i.e. would be non-lethal to a patient. Typically, from about 0.01 to 100 nM concentrations of putative
25 modulator compound may be used, for example from 0.1 to 10 nM.

- In a further aspect, a composition detected by a method of screening of the invention is provided for the treatment or prophylactic treatment of tumourigenesis or cancer or for the treatment or prophylactic treatment of neuropathology. The composition detected by
30 a method of screening can be used for the manufacture of a medicament for the treatment or prophylactic treatment of tumourigenesis or cancer or even diabetes, or for the manufacture of a medicament for the treatment or prophylactic treatment of neuropathology or the inhibition of neuronal degeneration.

- 35 Performance of a screening assay method according to the various aspects above may be followed by isolation and/or manufacture and/or use of a compound, substance or

molecule which tests positive for ability to interfere with or modulate the neuronal differentiation, neuronal development or cell proliferation.

The compounds thus identified may be formulated into compositions for use in the
5 diagnosis, prognosis or therapeutic treatment. Thus, the present invention also extends, in further aspects, to pharmaceutical formulations comprising one or more inhibitory or modulatory compound as obtainable by a screening method as provided herein.

A compound which has been identified as described above, may be manufactured and/or
10 may be used in the preparation, i.e. the manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals.

Not only the use of compounds which have been identified by a method of screening of
15 the invention, but also the use of a cleaved teneurin product is provided for the manufacture of a medicament for the treatment or prophylactic treatment of tumourigenesis or cancer or neuropathology.

Whether the compound which has been identified as described above is a polypeptide,
20 antibody, peptide, nucleic acid molecule, small molecule, mimetic or other pharmaceutically-useful compound according to the present invention, or a cleaved teneurin product that is to be given to an individual, administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show
25 benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors.

30 Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may include, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or
35 other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution,

- 5 dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution

- 10 which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

15

Examples of techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

- 20 The agent may be administered in a localised manner to the brain or other desired site, e.g. tumour tissue, or it may be delivered systemically in a manner such that it targets the brain or other cells.

- 25 Further provided is a composition comprising a cleaved teneurin product and a cellular target of the cleaved teneurin product wherein said target might be without limitation PML, Zic, or ponsin, or any target identified by expression array analysis (Table 1 and 2). The combination of the cleaved teneurin product and its cellular target may be used as a pharmaceutical or for the manufacture of a medicament for the treatment or prophylactic treatment of tumourigenesis or cancer or neurodevelopmental or neuroregenerative disease. The production or administration of such a pharmaceutical for use in the
- 30 diagnosis, prognosis or therapeutic treatment will be performed as hereinabove described.

Examples

- 35 The examples are described for the purposes of illustration and are not intended to limit the scope of the invention. Other embodiments of the invention will occur to those skilled in the art in the light of these.

Methods of molecular genetics, protein and peptide biochemistry and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art. For example, standard methods in genetic engineering are carried out essentially as described in Sambrook et al., Molecular Cloning: A laboratory manual, 3rd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY, 2001 and antibody-related techniques according to: Using antibodies : a laboratory manual / Ed Harlow, David Lane. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press, c1999. xiv, 495 p.)

10

Antibodies and DNA constructs

The following antibodies and constructs are easily prepared by routine methods and/or are available commercially: anti-teneurin-2 (Rubin et al. (1999) Dev Biol 216: 195-209),
15 anti-VSV (affinity-purified peptide antibody described in Kreis (1986) Embo J 5, 931-41), anti-FLAG (M2, Stratagene), anti-GAL4 (DGB RK5C1, Santa Cruz Biotechnology Inc.), anti-PML (PG-M3, Santa Cruz), anti-myc (c-Myc 9E10, Santa Cruz); anti-HA (12CA5, Roche); Alexa594- and Alexa488-conjugated goat-anti mouse and goat anti-rabbit IgG (Molecular Probes), horseradish peroxidase coupled anti-mouse and anti-rabbit IgG
20 (Soccochim). An antiserum was raised against the N-terminal part of the cytoplasmic domain of teneurin-1 (aminoacids 1- 158; Minet et al. 1999) expressed as a His-tagged protein in E. coli and purified by affinity chromatography on a Nickel column (Quiagen). The IgG fraction of this antiserum was purified over Protein A Sepharose (Amersham) according to standard procedures.

25

Constructs: pFR-luc (luciferase reporter plasmid; Stratagene), pSV-β-Galactosidase (Promega), pCMV-AD, pCMV-BD and pBD-NF κ B (Stratagene), p-CMX-PML and p-CMX-PML-RAR (described in Doucas et al. (1993) Proc Natl Acad Sci U S A 90(20):9345-9), pEF-zic1 (described in Aruga et al. (1996) J Biol Chem. 271(2):1043-7), pXP2-APOE189
30 (luciferase reporter plasmid under the control of an apolipoprotein E promoter; described in Salero et al., (2001) J Biol Chem. 276(3):1881-8) are used below.

Teneurin-2 constructs

35 Seven different teneurin-2 constructs were used, these are namely BDAD-CTEY, BDAD-CTE, BDAD-CT, BDAD-C, C, TE, TEY. They are named according to the teneurin-2 protein domains contained within their coding regions, namely CTEY (for Cytoplasmic,

Transmembrane, EGF-like and YD-repeats), containing the complete coding region of the long form of teneurin-2 including the cytoplasmic domain as well as the entire long form of the extracellular domain (described in Tucker et al. (2001) Dev Dyn 220: 27-39, Accession No. AJ279031); TEY, containing the entire long form of the extracellular domain; CTE, corresponding to a short splice variant of teneurin-2 containing the complete coding region of the short variant of teneurin-2 (Accession No. AJ245711) (described in Rubin et al. (1999) Dev Biol 216: 195-209); or TE, the short splice variant of teneurin-2 but without a cytoplasmic domain. Construct C represents the soluble cytoplasmic domain of teneurin-2. It encodes the first 372 amino acids of the teneurin-2 sequence as described in Rubin et al. 1999 (Rubin et al. (1999) Dev Biol 216: 195-209) followed by a VSV-G tag (an eleven amino acid sequence from residues 501 to 511 of the vesicular stomatitis virus (VSV) glycoprotein) for detection. In four constructs teneurin-2 was coupled to the GAL4 binding domain (BD) and the NF κ B activation domain (AD) generating BDAD-teneurin-2 fusion proteins. These constructs were cloned by multiple PCR. The product of the PCRs comprised bases 675-1118 of pCMV-BD coding for the GAL4 binding domain (BD), bases 703-1267 of pCMV-AD coding for the (AD) and bases 1-630 of teneurin-2 coding for the first 210 aminoacids of the cytoplasmic domain of teneurin-2 until the BpI site. These fragments were connected by the method of SOE (gene splicing by overlap extension, described in Horton R.M. (1995) Mol. Biotechnol., 3(2); 93-99) and the resulting construct was then cloned into the BamHI/BpI site of the preexisting pcDNA3/Neo vectors (Invitrogen) containing teneurin-2 constructs of different lengths as described above.

Transient transfections

HT1080 human fibrosarcoma (ATCC CRL-12012) and COS-7 cells (SV40-transformed kidney fibroblasts from the African green monkey, ATCC CRL-1651) were routinely maintained in DMEM medium (Dulbecco's Modified Eagles Medium) supplemented with 10 % FCS (fetal calf serum). For transient transfections the cells were seeded in 6-well plates or 4-well staining dishes (Greiner). Twelve hours later they were transfected with the expression vectors containing the constructs (1 μ g of each vector) described above and in Example 2 (Zic), Example 4 and Example 5 by using FUGENE-6 (3 μ l, 6 μ l or 9 μ l for one, two to three, or four different plasmids, respectively). The cells were treated with the following substances at least five hours after transfection: ALLN (25 μ g/ml; N-acetyl-leu-leu-norleu-AL; Sigma); tunicamycin (2 μ g/ml; Sigma) or lactacystin (10 μ M; e.g. Sigma) for four or eight hours prior to harvesting. Twenty-four hours after transfection the cells were rinsed in PBS (Phosphate-buffered saline) and processed for either measuring

luciferase and β -galactosidase activities, western blotting or immunofluorescence, essentially as described below.

Stable cell lines

- 5 Construct C was subcloned into the ecdyson-inducible expression vector pIND (Invitrogen) and transfected into EcR 293 cells according to the manufacturer's manual (Invitrogen) (EcR cell lines have been stably transformed with the regulatory vector, pVgRXR, for use in the Ecdysone-Inducible Mammalian Expression System. The cell
 10 lines express the ecdysone receptor, which regulates muristerone-dependent induction from pIND and pIND(SP1). Clones were tested for the inducible expression of construct C by the addition of increasing concentrations of Ponasterone (1-10 μ g/ml; Invitrogen) by immunoblotting using anti-VSV antibodies.

15 Luciferase and β -galactosidase assays

- The cells were lysed by adding reporter lysis buffer (Promega). Serial dilutions of the lysed cell suspension were then pipetted into Microlite™ luciferase plates (Dynex Technologies) and the luciferase activity was measured in a Microlumat (LB96P, EG+G Berthold) by automatic injection of luciferin substrate solution (2 mM luciferin, 100 mM ATP in 250 mM glycine pH 7.8, 150 mM MgSO₄). All luciferase activities were normalised with respect to the transfection efficiency by co-transfected a β -galactosidase vector. To determine β -galactosidase activity the diluted cell suspensions were incubated with the substrate solution (4.5 mM 2-nitrophenyl- β -D-galactopyranoside in 0.2 M Na-phosphate, 25 2 mM MgCl₂, 0.1 mM β -mercaptoethanol) for 30 min at 37°C. To stop the enzymatic reaction, three times the sample volume of 1 M Na₂CO₃ was added and the OD was measured at 405 nm in a microplate reader (BioRad).

Western blotting

- 30 Teneurin-2 constructs C, CT and CTE were extracted by adding SDS sample buffer containing 20 % β -mercaptoethanol directly to the cells (100 μ l/3.5cm plate). Extraction of the nuclear constructs BDAD and BDAD-C was achieved by performing nuclear fractionation. The transfected cells were harvested by scraping off the cell layer in 200 μ l
 35 lysis buffer (10 mM HEPES pH 7.5, 0.5 % triton X-100, 300 mM sucrose, 100 mM NaCl, 2 mM MgCl₂, protease inhibitors (Complete™, Roche Diagnostics) on ice and subsequent centrifugation for 10 min at 2000 rpm in an Eppendorf centrifuge. The

resulting pellet was resuspended in lysis buffer and centrifuged again. The final pellet was then dissolved in SDS sample buffer containing 20 % β -mercaptoethanol, 6 M urea and protease inhibitors (CompleteTM). Before loading on an 8 % SDS-PAGE gel (sodium dodecyl sulfate - polyacrylamide gel electrophoresis), DTT was added to a final concentration of 10 mM.

The transmembrane constructs BDAD-CTE and BDAD-CTEY were extracted from the cells by the following procedure. The cells were extracted on ice by 200 μ l of a hypotonic buffer (2 mM Na-phosphate buffer pH 7.5, 20 mM KCl, 1 mM β -mercaptoethanol), 5 scraped off and centrifuged for 10 min at 8000 rpm at 4°C in an Eppendorf centrifuge. The resulting pellet was reconstituted in 100 μ l of detergent buffer (50 mM Tris pH 8, 1 % NP40, 150 mM NaCl, 5 mM EDTA, 6 M urea, protease inhibitors (CompleteTM), incubated for 20 min at 37°C and centrifuged for 10 min at 13'000 rpm. An equal volume of SDS sample buffer containing 20 % β -mercaptoethanol, 6 M urea and protease inhibitors (CompleteTM) was added to the supernatant and incubated for 1 hour at 52°C. After DTT was added (10 mM), the samples were loaded on a 6 % SDS-PAGE gel.

The gels were transferred to PVDF (polyvinylidene fluoride) membranes. The proteins were detected by anti-GAL4 antibody (BDAD and BDAD-C) or by anti-teneurin-2 serum (BDAD-CTE and BDAD-CTEY), horseradish peroxidase coupled secondary antibodies and ECL SuperSignal® (Pierce).

Immunofluorescence

25 The cells grown on 4-well staining dishes (Greiner) were fixed with 4 % PFA for 30 min at room temperature, and permeabilised with 0.1 % Triton X-100 for 5 min. Incubation with primary antibodies was performed for 60 min and that with secondary antibodies for 30 min both at room temperature whereas the cells were washed in PBS after each incubation. Finally the specimens were mounted in Moviol (Hoechst, Frankfurt Germany) 30 and examined and photographed using a Zeiss Axiophot microscope (Carl Zeiss Ltd.) connected to a 3CCD camera (Sony).

Microarray analysis

Microarray analysis was performed using Affymetrix HG-U133A GeneChipsTM 35 (Affymetrix, Santa Clara, USA). 10 μ g of total RNA (isolated from EcR-293 cells (Invitrogen)) was reverse transcribed using the SuperScript Choice system for cDNA

synthesis (Life Technologies) according to the protocol recommended by Affymetrix (GeneChip Expression Analysis: Technical Manual (2001) p. 2.1.14-2.1.16). The oligonucleotide used for priming was 5'-ggccagtgaattgtataacgactcactataggaggcg-(t)₂₄-3' (SEQ ID NO: 9). Double-stranded cDNA was cleaned by phenol:chloroform extraction and the aqueous phase removed by centrifugation through Phase-lock Gel (Eppendorf). In vitro transcription was performed on 1 µg of cDNA using the Enzo BioArray High Yield RNA transcript labelling kit (Enzo Diagnostics, USA) following the manufacturer's protocol. The cRNA was cleaned using RNAeasy clean-up columns (Qiagen). To improve the recovery from the columns the elution water was spun into the matrix at 27 g and then left for one minute prior to the standard 8000 g centrifugation recommended by Qiagen. This low speed wetting step gave nearly double the yield of eluted RNA. The cRNA was fragmented by heating in 1x fragmentation buffer (40 mM Tris-acetate pH 8.1, 100 mM KOAc, 30 mM MgOAc). 10 µg of fragmented cRNA were hybridised to a HG-U133A GeneChip (Affymetrix) using their standard procedure (45°C, 16 hours). Washing and staining was performed in a Fluidics Station 400 (Affymetrix) using the protocol EukGE-WS2v4 and scanned in an Affymetrix GeneChip scanner. Chip analysis was performed using the Affymetrix Microarray Suite v5 (target intensity 500 used for chip scaling) and GeneSpring 4.2.1 (Silicon Genetics). Changes in gene expression were assessed by looking for concordant changes between replicates using a signed Wilcoxon rank test (as recommended by Affymetrix). The "change" p-value threshold was < 0.003 for increase and > 0.997 for decrease. After concordance analysis these values become < 9 × 10⁻⁶ and > 0.999991 respectively. Any gene whose detection p-value was > 0.05 in all experimental conditions was discarded from the analysis as being unreliable data.

Example 1: Localisation of the teneurin-2 cytoplasmic domain to the nucleus and its co-localization with PML

This Example demonstrates that teneurin co-localizes with PML (promyelocytic leukaemia protein) in nuclear bodies. It was found that the cytoplasmic domain of teneurin-2 (referred to as construct C) is translocated to the nucleus if transfected into human HT1080 fibrosarcoma cells. Transfection of HT1080 cells with construct C led to accumulation of the cytoplasmic domain in the nucleus, where its presence was confined to discrete spots within the nucleus. In contrast, the immunofluorescence staining pattern obtained with the transmembrane version of teneurin-2 (construct TEY) showed accumulation of the protein on the cell surface.

The nuclear localisation reflected a very similar punctuate pattern obtained by staining for PML protein (reviewed in Seeler et al. (1999) *Curr Opin Genet Dev.* 9(3):362-7; or Salomoni and Pandolfi (2002) *Cell* 108, 165-70) and is thus very suggestive of nuclear bodies termed PODs (promyelocytic oncogenic domains) or PML bodies. Double-
5 immunofluorescent stainings of C transfected cells showed substantial overlap of PML staining with that of the cytoplasmic domain of teneurin-2.

Since PML bodies are involved in a number of functions associated with transcriptional control (reviewed in Zhong et al. (2000) *Nat Cell Biol.* 2(5):E85-90), the colocalisation of
10 teneurin-2 and PML in nuclear bodies was further investigated by cotransfected C with PML, or C with PML-RAR (PML - retinoic acid receptor). Transfection of PML into cells containing endogenous PML protein leads to a massive enlargement of the nuclear bodies (Doucas et al. (1996) *Biochim Biophys Acta.* 1288(3):M25-9), whereas
15 transfection of PML-RAR results in the destruction of the PML body architecture (Mu et al. (1994) *Mol Cell Biol.* 14(10):6858-67). The present inventors also observed these effects. An equal staining pattern was detected after cotransfection of PML and C, where teneurin-2C (i.e. the cytoplasmic domain) was found in the enlarged PML bodies.
Furthermore destruction of the PML body architecture after transfection with PML-RAR
also changed the staining pattern with co-transfected C, which was no longer
20 accumulated in discrete spots in the nucleus but seemed to be expressed homogeneously throughout the cells. These results suggest the presence of teneurin-2 C within nuclear bodies thus supporting a putative transcriptional regulatory function of the cytoplasmic domain of teneurin-2.

25 Example 2: Teneurin-2 inhibits Zic transcriptional regulatory activity

In this Example, it was determined whether the zinc finger transcription factor Zic, a vertebrate homologue of opa would influence, or be influenced by, the cytoplasmic domain of teneurin-2. When both proteins, the cytoplasmic domain of teneurin-2 and Zic,
30 were expressed in HT1080 cells by transient transfections, a marked down-regulation (over ten-fold) of teneurin-2 C was observed compared to its usual expression level. In contrast, co-transfection of the two constructs had no effect on the Zic level. This effect was specific for teneurin-2 since BDAD was not down-regulated by the presence of Zic in an analogous analysis. The Zic induced downregulation of teneurin-2 C was
35 counteracted by the addition of the proteasome inhibitor lactacystin. By immunofluorescence staining of the transfected cells we observed that Zic-transfected

cells revealed a relatively diffuse nuclear staining of Zic and in nuclei containing high amounts of Zic protein, the punctuate staining of teneurin-2 C was not seen.

In order to examine a potential effect of the teneurin-2 C on the transcriptional activity of Zic, EcR 293 cells stable transfectants were produced. In these cells teneurin-2 C was only expressed upon addition of ponasterone, which induces expression of the cytoplasmic domain of teneurin-2. These cells were transiently transfected with Zic and the ApoE-luciferase reporter construct known to be activated by Zic. The presence of Zic led to a dramatic increase in luciferase acitivity. After the induction of teneurin-2 C by ponasterone a marked reduction in the expression level of the reporter gene was observed. These results suggested that the cytoplasmic domain of teneurin-2 has an inhibitory effect on the transcriptional activity of Zic and this effect is more pronounced in the presence of ALLN which was shown to stabilize teneurin-2 C.

15 Example 3: Functional interaction of teneurin-1 with ponsin

Yeast two hybrid screens using the cytoplasmic domains of teneurin-1 and -2 as bait were carried out to determine if teneurins interact with other proteins. The screen was performed with the DupLEX-A™ system (OriGene Technologies, Inc.) according to their User's Manual (Version 2.9 8/98). First, the entire cytoplasmic domains (aminoacids 1-300 of teneurin-1; Minet et al. 1999 and aminoacids 1-376 of teneurin-2; Rubin et al. 1999) were used. However, both of these constructs resulted in self-activation of the LexA-dependent target genes and thus could not be used to search for interaction partners. We next split each of the cytoplasmic domains in two parts Ten-1a, Ten-1b and Ten-2a, Ten-2b, respectively (Ten-1a represents aminoacids 1-155 and Ten1b 156-300 of teneurin-1 and Ten-2a represents aminoacids 1-168 and Ten2b 169-376 of teneurin-2). Both, Ten-1a and Ten-2a were still self-activating the LexA-dependent genes, implying a possible function for teneurins in transcriptional control. Ten-1b and Ten-2b could be used to screen a whole mouse 19day embryo DupLex-A cDNA library (OriGene). The screen with Ten-1b resulted in an interacting cDNA clone that encoded the third SH3 domain of a protein called ponsin (Mandai et al. 1999).

The binding of full length ponsin to the cytoplasmic domain of teneurin-1 was confirmed by co-transfection and co-immunoprecipitation of a myc-tagged posing expression plasmid (ponsin-2 in pCMV5-Myc as described in Mandai et al. 1999) and the full length cytoplasmic domain of teneurin-1 (aminoacids 1- 300; Minet et al. 1999) in Cos-7 cells. Cultures of Cos-7 cells (3.5 cm dishes at 70% confluency) were co-transfected with 1µg

of each DNA using fugene (Roche). 48 hours later cell layers were washed with PBS and the cell layers frozen on dry ice to break up cells, which were then scraped into 300 µl of PBS including proteinase inhibitors (Complete proteinase inhibitor cocktail tablets, Roche). This cell extract was centrifuged at 14'000rpm. To the supernatant 150 µl of 5 RIPA buffer (150mM NaCl; 50mM Tris-HCl pH 8.0; 1% NP-40; 0.5% Deoxycholic acid; 0.1% SDS; 50mM NaF; 0.5mM Na₃VO₄) was added followed by immunoprecipitation with 1µg of anti-teneurin-1 IgG. The cell lysate was incubated with the anti-Ten-1 antibody for 90 minutes slowly rotating at 4°C. Then 30 µl of protein A Sepharose beads (4 Fast Flow; Amersham) washed in RIPA buffer were added. After 60 minutes of rotation at 4°C the 10 beads were collected by centrifugation and washed three times with PBS. The beads were eluted by boiling in 50 µl of SDS-PAGE sample buffer and analyzed by western blotting. The eluate was run in two parallel lanes on a 10% SDS-PAGE and blotted to PVDF membranes. The immunoprecipitated teneurin-1 was detected with an anti-FLAG antibody and the co-precipitated ponsin by anti-myc followed by secondary antibodies 15 and detection using a chemiluminescence kit (ECL, Amersham). Whereas immunoprecipitated teneurin-1 contained ponsin, precipitates with control IgG did not contain any detectable ponsin.

The interaction of teneurin-1 with ponsin was further confirmed by immunohistochemistry 20 of co-transfected cells. Transfection of ponsin alone results in a cytoplasmic and cytoskeleton-associated expression pattern, whereas the soluble cytoplasmic domain of teneurin-1 accumulates in the nucleus. Upon co-transfection of the cytoplasmic domain of teneurin-1 and ponsin, ponsin translocates together with teneurin-1 into the nucleus. Thus teneurin-1 co-localizes with and binds to ponsin, which means that they will 25 influence each others function in the regulation of cell adhesion, cytoskeleton assembly and possibly transcription.

Example 4: Morphological changes of cells expressing the cytoplasmic domain of teneurin-2

30 Cell extracts from COS-7 green monkey kidney fibroblasts were prepared 24 hours after transfection with CTEY, TEY, CTE and TE constructs and analyzed by SDS-PAGE and immunoblotting with anti-teneurin-2 serum. Each construct resulted in the presence of a major band of roughly the expected size of 280kD, 240kD, 120kd and 80kd, respectively. 35 The proteins without the cytoplasmic tails (TEY and TE) were about 40kd smaller than the corresponding proteins with these domains present (CTEY and CTE). Immunostaining of the transfected cells without permeabilization prior to antiserum

incubation revealed the presence of the extracellular domains of teneurin-2 on the cell surface. The morphology of the cells expressing the constructs including the cytoplasmic domains was very different from the ones without the cytoplasmic domain. Whereas CTEY and CTE induced prominent filopodia in the transfected cells, TEY and TE were present in cells with smooth surfaces. This implies an interaction of the teneurin-2 cytoplasmic domain with cytoskeletal components.

Example 5: Homophilic binding of teneurin induces cleavage

To isolate stable cell lines expressing teneurin-2 constructs human HT1080 fibrosarcoma cells were transfected and replated to allow clonal growth of the transfected cells. Several clones representing the constructs were screened for recombinant protein expression by immunofluorescence as well as by immunoblotting. Phalloidin-staining and detection of the recombinantly expressed teneurin-2 proteins with the anti-teneurin-2 antibody by immunohistochemistry was done as follows:

24 to 72 hours after transfection the cells were rinsed once with Ca^{2+} - and Mg^{2+} -free PBS (PBS CMF) and either fixed with 4% formaldehyde in PBS CMF for immunohistochemistry or scraped off the dish and solubilized in SDS-PAGE sample buffer for Western blot analysis. To permeabilize the fixed cells 0.2% Triton X-100 in PBS CMF was applied for 15 min. following this step the permeabilized cells, like the intact cells, were rinsed with PBS CMF and incubated in blocking buffer (3% BSA in PBS CMF) for 15 min. The primary antibodies (anti-teneurin-2, anti-VSV tag, as well as the fluorescein-coupled secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) were diluted in the blocking buffer. Along with the secondary antibody phalloidin coupled to rhodamine was incubated (Sigma, Buchs, Switzerland). After each of the incubations, cells were rinsed in PBS CMF. For viewing, cells were mounted in Moviol (Calbiochem, La Jolla, CA). For Western blot analyses samples were separated on a 10% SDS-PAGE, transferred onto a nylon membrane, and treated as described by Hagios et al. (1996) J Cell Biol. 134(6):1499-512.

Teneurin-2 containing cellular extracts for immunoblotting were prepared as follows: After washing the cells on 5 cm culture dishes with cold PBS, plates were frozen at minus 20°C. After thawing, they were extracted for 30min on ice with 600 μ l of hypotonic buffer (20mMKCl, 2mM Na-phosphate pH 7.0/ 1mM β -mercaptoethanol). Cells were collected by scraping with a rubber policeman and transferred into Eppendorf tubes. After spinning for 10 minutes at maximum speed the pellet was dissolved at 37°C for 20min in 60 μ l

detergent buffer (150mM NCI/ 50mMTris pH8/ 1% NP-40/ 6M urea, 5mM EDTA) per plate. An equal volume of SDS-PAGE sample buffer (0.2M Tris-HCl pH6.8/ 4%SDS/ 17.4% glycerol/ 20% β -mercaptoethanol/ 6M urea) was added and the sample was incubated for 1 hour at 52°C. The samples were separated on SDS-PAGE and 5 transferred to PVDF membranes. The teneurins were detected by the anti-teneurin antiserum (Rubin et al. (1999) Dev Biol. 216(1):195-209) and the signals revealed using the ECL western blotting system (Amersham).

We were able to select several clones of the two constructs, TEY and TE, that lack the 10 cytoplasmic domain. The clones expressing the long form of the extracellular domain (TEY) showed a much flatter morphology than either the parental cells (HT1080) or the cells expressing the short teneurin extracellular domain (TE) as can be seen both on the phase contrast pictures as well as after phalloidin staining of the actin cytoskeleton. Despite their flat morphology the clones of TEY did not contain a more pronounced actin 15 cytoskeleton than the parental cells and all cells revealed mostly cortical actin staining.

In addition to their flat phenotype we noticed that the cell clones of TEY grew in epithelial cell-like patches suggestive of increased cell-cell adhesion, whereas the parental cells and clone TE grew as dispersed fibroblast-like cells. Therefore, we investigated whether 20 or not these clones showed increased cell-cell adhesion in an aggregation assay of cells in suspension. Cells were harvested by incubation with 0.2% EDTA, pelleted by centrifugation and resuspended at 2.5×10^5 cells/ml of Leibovitz L15 medium (Gibco) containing 1% fetal calf serum (Gibco). Three milliliters of each cell suspension were added to 5cm bacterial plates (Sterilin) and incubated at 37°C on a rotary shaker at 25 80rpm. Photographs were taken at 15min intervals and cell aggregation was analyzed by counting single cells versus cells in double, triple or higher number aggregates. The aggregation index was calculated as $N_0 - N_t / N_0$, where N_0 is the initial number of particles corresponding to the total number of cells, and N_t is the number of remaining particles at the incubation time point t. While the parental HT1080 cells as well as the cells containing 30 the TE construct remained as single cells, all clones expressing the long teneurin-2 extracellular domain (TEY) aggregated into clumps of cells. The presence of the extracellular domain of teneurin-2 on these cells resulted in their homophilic aggregation. Quantitative comparison of the cell aggregation showed that after 30 minutes of 35 incubation all TEY cell lines had already approached maximal aggregation values, whereas the HT1080 and TE cells did not aggregate even after 90 minutes of incubation.

Further the effect of the expression of the teneurin-2 constructs on Nb2a neuroblastoma cells was investigated. As reported in Rubin et al. (1999) Dev Biol. 216(1):195-209, expression of CTE constructs in Nb2a cells led to the induction of filopodia and enlarged growth cones. This effect was not seen after transfection of the TE construct lacking the cytoplasmic domain and the protein mainly localized to cell bodies and not to neurites. This suggests that the cytoplasmic domain is required for the translocation of the teneurin protein to neurites and growth cones. The transfection of the longer constructs CTEY and TEY resulted in quite different teneurin-2 expression patterns. Both of these proteins were expressed on the cell surfaces and were heavily enriched in cell-cell contact areas giving further support for the promotion of homophilic interactions between these neuronal cells. The CTEY expression led in addition to the accumulation of actin to these teneurin-rich cell-cell contacts as revealed by phalloidin staining, which was not the case for the TEY construct. This provides further support for an interaction between teneurin-2 and the actin cytoskeleton through its cytoplasmic domain.

15

Example 6: Cleavage and stabilization of the cytoplasmic domain

The nuclear localization of the cytoplasmic domain and its transcriptional regulatory role would mean that the wild-type transmembrane teneurin-2 would have to be specifically cleaved in or at the plasma membrane possibly upon ligand binding. The cytoplasmic domain would thereby be released and translocated to the nucleus. To establish this process, fusion proteins of full length teneurin-2 or smaller fragments comprising the transmembrane domain, attached to a GAL4 DNA binding domain (BD) and a NF κ B activation domain (AD) were introduced into HT-1080 and Cos-7 cells. Cleavage of the fusion protein and translocation of BDAD-C to the nucleus can be detected by binding of BD to specific GAL4 binding sequences on a co-transfected luciferase reporter plasmid, which results in the subsequent initiation of luciferase gene expression through AD.

BDAD and BDAD-C serving as positive controls in this experiment were detectable on a Western blot of nuclear extract by anti-GAL4 antibodies. In addition, BDAD-C accumulation in the nucleus was confirmed by immunofluorescent staining of permeabilised cells. At the same time BDAD-CTE and BDAD-CTEY could be identified as part of the (plasma) membrane by western blot of a membranous cell fraction and by immunofluorescence of non-permeabilised cells.

35

For analysis of the luciferase activity induced by the teneurin-2 fusion constructs, HT1080 cells were cotransfected with the respective BDAD-teneurin-2 constructs, the luciferase

reporter plasmid as well as a β -Galactosidase construct for normalisation of transfection efficiencies. BDAD-CTE, BDAD-CT and BDAD-C led to an induction of luciferase activity over the negative control (BD construct). However, BDAD-CTEY being the largest fusion protein did not lead to a significantly enhanced activity. Cleavage of the shorter
5 constructs might be constitutive while cleavage of the full length construct might have to be specifically induced, for example by ligand binding.

As described in Example 5, teneurin-2 has been shown to bind homophilically by its extracellular domain and may induce cleavage and translocation of the cytoplasmic
10 domain of the BDAD-teneurin-2 fusion proteins. To test whether homophilic interaction of teneurin-2 represents a signal for cleavage of its cytoplasmic domain, BDAD-CTEY and as control BDAD-CT, were transfected into HT-1080 cell clones that constitutively express TEY or TE on their surface (described in Example 5 hereinabove) and the luciferase activity produced from the co-transfected reporter plasmid analysed. The
15 luciferase activities obtained were normalized to the transfection of the same constructs into wild type HT1080 cells. Luciferase activity obtained after transfection of BDAD-CTEY into the TEY cells was approximately 6-fold higher than after transfection of BDAD-CT while in TE cells the activity was not affected by the type of construct used for transfection. Thus, the C-terminal of the extracellular domain is required to induce the
20 cleavage of the cytoplasmic domain of teneurin-2.

In summary, the activity of the luciferase reporter gene originates from the cleavage of the BDAD-teneurin-2 fusion proteins at (or in the vicinity of) the membrane because it could be specifically upregulated by homophilic binding of full length but not shorter
25 truncated versions of teneurin-2 extracellular domains on the surface of the cell. BDAD attached to full length teneurin-2 (BDAD-CTEY) led to a significant induction of the luciferase gene only when processing was upregulated by homophilic binding of the extracellular C-terminal part of teneurin-2. In addition, this activation was not observed with the truncated teneurin-2 fusions described above. Nevertheless, the shorter
30 counterparts seemed to be cleaved without stimulation. Although not wishing to be bound by theory, the large BDAD-CTEY construct is expressed less efficiently than its shorter counterparts and the cleavage products might be down-regulated quickly in proteasomes. The induction of luciferase activity following transfection of BDAD-CTEY could indeed be markedly upregulated by the addition of protease inhibitors such as ALLN and
35 lactacystin. Similarly, CTE protein levels also increased as demonstrated by western blot. The addition of ALLN led to the stabilisation of two particular cleavage products, one of which corresponded to the size of the cytoplasmic domain alone.

Example 7: Identification of genes regulated by teneurin signalling

The cDNA encoding the cytoplasmic domain of teneurin-2 containing a C-terminal VSV-tag was cloned into the vector pIND (Invitrogen). EcR-293 cells (Invitrogen) containing the stably integrated plasmid pVgRXR (Invitrogen) were transfected with the pIND teneurin-2 plasmid encoding the cytoplasmic domain. Stable clones were selected and tested for the expression of the cytoplasmic domain of teneurin-2 after addition of ponasterone (Invitrogen). Cells of one positive clone termed K3 was used for the further analysis.

Parental EcR-293 cells and K3 cells were grown to 70% confluence before 10µM ponasterone was added to both cell cultures for 24 hours. Parallel cultures were kept without the addition of ponasterone. After 24 hours mRNA was isolated using Trizol reagent (Gibco) from four different cultures: K3 - ponasterone, K3 + ponasterone, ECR293 - ponasterone and ECR293 + ponasterone. This procedure was typically performed in duplicates, resulting in 8 mRNA batches. Each of these batches of mRNA was used to make probes to hybridize to Affymetrix chips (U133) containing oligonucleotides for the detection of 20'000 potential transcripts. Lists were derived that contained genes that were differentially expressed depending on the presence of ponasterone. Genes that were common to both lists of the two independently performed duplicates were investigated further and made up the entries of the four lists K3 up, K3 down (genes up- or down-regulated by ponasterone in K3 cells), EcR-293 up, EcR-293 down (genes up- or down-regulated by ponasterone in EcR-293 cells). To exclude any genes that were affected by ponasterone directly, any entries common to the lists of the ECR293 and K3 cells were discarded resulting in the final lists of genes up-regulated (Table 1) or down-regulated (Table 2) by the presence of the cytoplasmic domain of teneurin-2. Table 1 shows the genes up-regulated by the cytoplasmic domain and the ID number of the respective database assigned by Affymetrix. Table 2 shows the genes down-regulated by the cytoplasmic domain and the ID number of the respective database assigned by Affymetrix. Among the genes up- and down-regulated by teneurin-2 many are known to play a role in the regulation of cell growth, differentiation and apoptosis. A group of genes up-regulated by teneurin-2 correlates with genes known to be targets of p53 (Nr. 7, 23, 33, 51, 65 in Table 1). Another group of down-regulated genes corresponded to genes known to play a role in neuronal differentiation and synapse formation and function (Nr. 4, 5, 11, 12, 27, 28, 29, 30, 34, 35, 40, 56, 90 of Table 1). A group of genes down-regulated by teneurin-2 correlated with genes known to be glutathionylated and involved in the regulation of the redox status of cells (Nr. 3, 4, 11,

44, 46, 69 of Table 2). Another group of down-regulated genes corresponded to genes known to be targets of myc (Nr. 1, 3, 4, 11, 14, 31, 69 of Table 2).

Example 8: Proliferation assay

The effect of the expression of the cytoplasmic domain of teneurin-2 on cell proliferation was tested. K3 cells (EcR-293 cells (Invitrogen) containing the stably integrated plasmid pVgRXR (Invitrogen) and the pIND teneurin-2 plasmid encoding the cytoplasmic domain, described in Example 7) were cultured in the presence or absence of ponasterone, which induces expression of the cytoplasmic domain of teneurin-2. Typically, over a 5 day period, parallel cultures were fixed with 4% formaldehyde every day and cell numbers were determined by staining the cells with crystal violet (0.1% in H₂O). In the presence of ponasterone and thus in the presence of the cytoplasmic domain of teneurin, the K3 cells were retarded in their growth rate to about 50% of the untreated cells. Proliferation of EcR-293 cells without transfected cytoplasmic domain of teneurin-2 was not affected by the addition of ponasterone, proving that the growth retardation was specifically dependent on the presence of the cytoplasmic domain of teneurin-2.

Example 9: The cytoplasmic domain of teneurin-1 can be detected in nuclei of *C.elegans* embryo cells

Ten-1 is the *C.elegans* orthologue of the *Drosophila* pair-rule gene ten-m. We describe here the gene structure of *ten-1* encompassing two promoters that control the expression of two different *ten-1* transcripts. This results in the expression of two type II transmembrane protein variants differing in their cytoplasmic domains. The 5' ends of the *ten-1* cDNAs were determined by RT-PCR using splice leader 1 (SL1) as the 5' primer and a *ten-1* specific oligonucleotide as the 3' primer. cDNA fragments were prepared by RT-PCR using Superscript RNaseH(-) reverse transcriptase (Life Technologies). 5' cDNA ends were amplified with Expand HiFi polymerase (Roche) using SL1 as a 5' primer and the gene specific primer AGCACGTGTCGCTATCGTCG (SEQ ID NO: 10) using cDNA prepared from mixed stage worms. The RT-PCR reaction using mixed stage mRNA as template resulted in two products differing in size. By sequencing these bands two different cDNA species could be identified. One of them corresponded with a minor difference at the 5' end to the transcription start of the predicted open reading frame R16F6.4 and the other one contained in addition the predicted open reading frame F28F5.1 together with a newly discovered exon. Thus the *ten-1* gene is under the control of alternative promoters resulting in two different transcripts that encode two Ten-1

proteins differing in their N-terminal sequences. The long form contains N-terminal to a predicted transmembrane sequence a cytoplasmic domain of 218 aa whereas the short form has only 37 aa that are in common between both variants. The intracellular sequences do not contain any predicted domains but contain a consensus sequence for 5 tyrosine phosphorylation. The long form harbors a proline-rich stretch at the N-terminus and a potential bipartite nuclear localization signal. The N-terminal cytoplasmic domains are followed by a transmembrane domain making Ten-1 a type II transmembrane protein.

For DNA constructions 4 Kb of the upstream promoter where amplified with the primers
 10 CATTGGTCAATTGGCGGCCATT CGCAGACG (SEQ ID NO: 11) and
 ATTAGGCGGTGGGGTACCGCATT CG (SEQ ID NO: 12) and cloned into the Ascl/KpnI sites of pPD117.28 (A. Fire). 3 Kb of the downstream promoter where amplified with the primers GAATT CGCATGCAAATGTGAAGCATG (SEQ ID NO: 13) and
 CCACCAGGTACCGGATCACCATT GTTC (SEQ ID NO: 14) and cloned into the
 15 SphI/KpnI sites of pPD117.28 (A. Fire). DNA encoding the long intracellular domain was amplified with the primers CAGAGTGC GGCCGCCGTGCGTT CG (SEQ ID NO: 15) and GGCTAGGAATT CATT CCATT GGATGG (SEQ ID NO: 16). DNA encoding the short intracellular domain was amplified with the primers
 TTACAATTTTCAGGCGGCCGCAAGTTGGC (SEQ ID NO: 17) and
 20 GGCTAGGAATT CATT CCATT GGATGG (SEQ ID NO: 18).

For antibody production, anti-Ten-1 antibodies were raised against the Ten-1 specific peptides from the N-terminus of the long variant (MFQHRTTNAQGPPPNRPMR) (SEQ ID NO: 19) and the common C-terminus (PAHQSGLLASVHSWKFRKSE) (SEQ ID NO: 20). The peptides where synthesized and the rabbits immunized at Neosystem (Strasburg, France). All sera were affinity purified using the respective peptides coupled to CNBr-activated Sepharose 4B columns according to standard procedures.

Antibodies against the N-terminus of the long ten-1 variant (anti-N) and the one against 30 the C-terminus of the protein (anti-C) were used to stain early embryos of *C. elegans*. Anti-C stained all membranes while anti-N stained in addition also the nuclei of the Ten-1 expressing cells. This was also prevalent in the cells lining the gut where anti-C stained the cell membranes and anti-N stained the predominantly the nuclei. Although not wishing to be bound by theory, the endogenous Ten-1 might normally be proteolytically 35 processed and the translocation of the cytoplasmic domain could be a physiological process in Ten-1 signaling. The nuclear translocation of the long cytoplasmic domain of Ten-1 can be confirmed by overexpression of both cytoplasmic domains as GFP fusion

proteins under a heat shock promoter. Transient expression of these constructs revealed that the long cytoplasmic domain accumulated in the nuclei of the cells whereas the short form remained cytoplasmic.

- 5 Ten-1 was characterized as a novel transmembrane protein of *C. elegans* and is required for gametogenesis, early embryogenesis, and hypodermal cell migration. In later stages of development it is involved in neuronal migration and pathfinding, distal tip cell migration and establishing of the somatic gonad. Furthermore, it is also required for pharynx and gut development as well as for proper defecation. Although not wishing to
- 10 be bound by theory, Ten-1 might act as a receptor for morphogenetic cues and it directly signals to the nucleus by proteolytic release of its cytoplasmic domain from the cell membrane and by translocation to the nucleus.

Table 1:

Nr.	Affimetrix ID	Unigene ID	Locus Link ID	Ref Seq (NM_)/Gene Bank ID	Ref Seq ID + Annotation
1	200620_at	Hs.11441	9528	NM_004872.1	NM_004872 chromosome 1 open reading frame 8
2	200710_at	Hs.82208	37	NM_000018.1	NM_000018 acyl-Coenzyme A dehydrogenase, very long chain precursor
3	200804_at	Hs.74637	7009	NM_003217.1	NM_003217 testis enhanced gene transcript (BAX inhibitor 1)
4	200848_at	Hs.4113	10768	AA479488	NM_006621 S-adenosylhomocysteine hydrolase-like 1
5	200849_s_at	Hs.4113	10768	AA479488	NM_006621 S-adenosylhomocysteine hydrolase-like 1
6	201057_s_at	Hs.7844	2804	NM_004487.1	NM_004487 golgi autoantigen, golgin subfamily b, macrogolgin (with transmembrane signal),
7	201236_s_at	Hs.75462	7832	NM_006763.1	NM_006763 BTG family, member 2
8	201301_s_at	Hs.77840	307	BC000182.1	NM_001153 annexin IV
9	201302_at	Hs.77840	307	NM_001153.2	NM_001153 annexin IV
10	201494_at	Hs.75693	5547	NM_005040.1	NM_005040 prolylcarboxypeptidase (angiotensinase C)
11	201565_s_at	Hs.180919	3398	NM_002166.1	NM_002166 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
12	201566_x_at	Hs.180919	3398	D13891.1	NM_002166 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
13	201637_s_at	Hs.82712	8087	NM_005087.1	NM_005087 fragile X mental retardation-related protein 1
14	201663_s_at	Hs.50758	10051	NM_005496.1	NM_005496 SMC4 structural maintenance of chromosomes 4-like 1
15	201813_s_at	Hs.115740	9779	NM_014744.1	NM_014744 KIAA0210 gene product
16	201814_at	Hs.115740	9779	NM_014744.1	NM_014744 KIAA0210 gene product
17	201876_at	Hs.169857	5445	NM_000305.1	NM_000305 paraoxonase 2
18	201964_at	Hs.154919	23064	N64643	NM_015046 KIAA0625 protein
19	201965_s_at	Hs.154919	23064	NM_015046.1	NM_015046 KIAA0625 protein
20	202436_s_at	Hs.154654	1545	NM_000104.2	NM_000104 cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1
21	202437_s_at	Hs.154654	1545	NM_000104.2	NM_000104 cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1
22	203232_s_at	Hs.74520	6310	NM_000332.1	NM_000332 ataxin 1
23	203409_at	Hs.77602	1643	NM_000107.1	NM_000107 damage-specific DNA binding protein 2 (48kD)
24	203411_s_at	Hs.77886	4000	NM_005572.1	NM_005572 lamin A/C
25	203560_at	Hs.78619	8836	NM_003878.1	NM_003878 gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) precursor
26	203594_at	Hs.27076	8634	NM_003729.1	NM_003729 RTC domain containing 1
27	203789_s_at	Hs.171921	10512	NM_006379.1	NM_006379 sema domain,

					immunoglobulin domain (Ig), short basic domain, secreted, (semaphor
28	203810_at	Hs.41693	11080	BG252490	NM_007034 DhaJ (Hsp40) homolog, subfamily B, member 4
29	203999_at	Hs.154679	6857	NM_005639.1	NM_005639 synaptotagmin I
30	205352_at	Hs.78589	5274	NM_005025.1	NM_005025 protease inhibitor 12 (neuroserpin)
31	205934_at	Hs.153322	5334	NM_006226.1	NM_006226 phospholipase C, epsilon
32	207071_s_at	Hs.154721	48	NM_002197.1	NM_002197 aconitase 1
33	208478_s_at	Hs.159428	581	NM_004324.1	NM_004324 BCL2-associated X protein, isoform beta NM_138761 BCL2-associated X protein, isoform alpha NM_138762 BCL2-associated X protein, isoform gamma NM_138763 BCL2-associated X protein, isoform delta NM_138764 BCL2-associated X protein, isoform epsilon
34	208786_s_at	Hs.121849	81631	AF183417.1	NM_022818 microtubule-associated proteins 1A/1B light chain 3
35	208890_s_at	Hs.3989	23654	BC004542.1	NM_012401 plexin B2
36	208933_s_at	Hs.70333	51322	AI659005	NM_016628 WW domain-containing adapter with a coiled-coil region, isoform 1 NM_018604 NM_100264 WW domain-containing adapter with a coiled-coil region, isoform 2 NM_100486 WW domain-containing adapter with a coiled-coil region, isoform 3
37	208943_s_at	Hs.8146	7095	U93239.1	NM_003262 translocation protein 1
38	209091_s_at	Hs.136309	51100	AF263293.1	NM_016009 SH3-containing protein SH3GLB1
39	209167_at	Hs.5422	2824	AF016004.1	
40	209238_at	Hs.82240	6809	BE966922	NM_004177 syntaxin 3A
41	209268_at	Hs.6650	11311	AF165513.1	NM_007258 NM_007259 vacuolar protein sorting 45A NM_007259 vacuolar protein sorting 45A
42	209295_at	Hs.51233	8795	AF016266.1	NM_003842 tumor necrosis factor receptor superfamily, member 10b
43	209312_x_at	Hs.308026	3123	U65585.1	NM_002124 major histocompatibility complex, class II, DR beta 1 precursor
44	209707_at	Hs.62187	10026	AF022913.1	
45	209849_s_at	Hs.11393	5889	AF029669.1	NM_002876 RAD51 homolog C, isoform 2 NM_058216 RAD51 homolog C, isoform 1 NM_058217 RAD51 homolog C, isoform 3
46	209993_at	Hs.21330	5243	AF016535.1	NM_000927 ATP-binding cassette, sub-family B (MDR/TAP), member 1
47	210038_at			AL137145	
48	210039_s_at	Hs.211593	5588	L01087.1	NM_006257 protein kinase C, theta
49	211061_s_at	Hs.172195	4247	BC006390.1	NM_002408 alpha-1,6-mannosyl-glycoprotein beta-1,2-N-acetylglucosaminyltransferase
50	211769_x_at	Hs.272168	10955	BC006088.1	NM_006811 tumor differentially expressed 1
51	211833_s_at	Hs.159428	581	U19599.1	NM_004324 BCL2-associated X protein, isoform beta NM_138761

					BCL2-associated X protein, isoform alpha NM_138762 BCL2-associated X protein, isoform gamma NM_138763 BCL2-associated X protein, isoform delta NM_138764 BCL2-associated X protein, isoform epsilon
52	212120_at	Hs.250697	23433	BF348067	NM_012249 ras-like protein
53	212266_s_at	Hs.166975	6430	AW084582	NM_006925 splicing factor, arginine-serine-rich 5
54	212359_s_at	Hs.65135	23053	W89120	
55	212408_at	Hs.234265	26092	AK023204.1	
56	212820_at	Hs.13264	23312	AB020663.1	NM_015263 rabconnectin-3
57	212998_x_at	Hs.73931	3119	AI583173	NM_002123 major histocompatibility complex, class II, DQ beta 1 precursor
58	213056_at	Hs.96427	23150	AU145019	
59	213258_at	Hs.288582		BF511231	
60	213400_s_at	Hs.76536	6907	AV753028	NM_005647 transducin beta-like 1X
61	213624_at	Hs.42945	10924	AA873600	
62	214098_at	Hs.21554	23285	AB029030.1	
63	214449_s_at	Hs.250697	23433	NM_012249.1	NM_012249 ras-like protein
64	215719_x_at			X83493.1	
65	215785_s_at	Hs.258503	26999	AL161999.1	
66	216231_s_at	Hs.75415	567	AW188940	NM_004048 beta-2-microglobulin
67	216860_s_at	Hs.339699	10220	AF028333.1	NM_005811 growth differentiation factor 11
68	217127_at			AL354872	
69	217731_s_at	Hs.239625	9445	NM_021999.1	NM_021999 integral membrane protein 2B
70	217858_s_at	Hs.172788	51566	NM_016607.1	NM_016607 ALEX3 protein
71	218007_s_at	Hs.108957	51065	NM_015920.1	NM_015920 ribosomal protein S27-like protein
72	218084_x_at	Hs.333418	53827	NM_014164.2	NM_014164 FXYD domain-containing ion transport regulator 5
73	218107_at	Hs.289069	80232	NM_025160.1	NM_025160 hypothetical protein FLJ21016
74	218113_at	Hs.160417	23670	NM_013390.1	NM_013390 transmembrane protein 2
75	218132_s_at	Hs.15580	79042	NM_024075.1	NM_024075 LENG5 protein
76	218248_at	Hs.19525	63901	NM_022074.1	NM_022074 hypothetical protein FLJ22794
77	218341_at	Hs.72531	79717	NM_024664.1	NM_024664 hypothetical protein FLJ11838
78	218603_at	Hs.6679	51696	NM_016217.1	NM_016217 hHDC for homolog of Drosophila headcase
79	218634_at	Hs.268557	23612	NM_012396.1	NM_012396 pleckstrin homology-like domain, family A, member 3
80	218765_at	Hs.33724	51092	NM_015996.1	NM_015996 CGI-40 protein
81	218773_s_at	Hs.279754	22921	NM_012228.1	NM_012228 pilin-like transcription factor NM_016064
82	218853_s_at	Hs.57549	56180	NM_019556.1	NM_019556 hypothetical protein dJ473B4
83	219236_at	Hs.235873	79957	NM_024897.1	NM_024897 hypothetical protein FLJ22672
84	219329_s_at	Hs.9527	51374	NM_016085.1	NM_016085 apoptosis related protein APR-3 NM_080592 apoptosis related protein APR-3
85	219694_at	Hs.91165	54491	NM_019018.1	NM_019018 hypothetical protein

					FLJ11127
86	219880_at	Hs.94037	64942	NM_022907.1	NM_022907 hypothetical protein FLJ23053
87	220261_s_at	Hs.5268	55146	NM_018106.1	NM_018106 hypothetical protein FLJ10479
88	220387_s_at	Hs.142245	11147	NM_007071.1	NM_007071 HERV-H LTR- associating 3
89	220520_s_at	Hs.163629	54830	NM_017681.1	NM_017681 hypothetical protein FLJ20130
90	221004_s_at	Hs.111577	81618	NM_030926.1	NM_030926 integral membrane protein 3
91	221449_s_at	Hs.23047	81533	NM_030790.1	NM_030790 hypothetical protein CDA08
92	221487_s_at	Hs.111680	2029	AF157510.1	NM_004436 endosulfine alpha
93	221958_s_at	Hs.250746	79971	AA775681	NM_024911 hypothetical protein FLJ23091
94	222138_s_at			AF158978.1	
95	222209_s_at			AK000684.1	
96	55093_at	Hs.86392	54480	AA534198	
97	56256_at	Hs.33724	51092	AA150165	NM_015996 CGI-40 protein

Table 2:

Nr.	Affimetrix ID	Unigene ID	Locus Link ID	Ref Seq (NM_)/Gene Bank ID	Ref Seq ID + Annotation
1	200659_s_at	Hs.75323	5245	NM_002634.2	NM_002634 prohibitin
2	200685_at	Hs.11482	9295	AU146237	NM_004768 splicing factor, arginine/serine-rich 11
3	200691_s_at	Hs.3069	3313	BC000478.1	NM_004134 heat shock 70kD protein 9B (mortalin-2)
4	200692_s_at	Hs.3069	3313	NM_004134.1	NM_004134 heat shock 70kD protein 9B (mortalin-2)
5	200831_s_at	Hs.119597	6319	AA678241	NM_005063 stearoyl-CoA desaturase (delta-9-desaturase)
6	200884_at	Hs.173724	1152	NM_001823.1	NM_001823 creatine kinase, brain
7	200987_x_at	Hs.152978	10197	AA758755	NM_005789 proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki)
8	201013_s_at	Hs.117950	10606	AA902652	NM_006452 phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoribosylamin oimidazo
9	201016_at	Hs.4310	1964	BE542684	NM_001412 eukaryotic translation initiation factor 4C
10	201017_at	Hs.362973		BE542684	
11	201231_s_at	Hs.254105	2023	NM_001428.1	NM_001428 enolase 1 NM_005945
12	201284_s_at	Hs.78223	327	NM_001640.2	NM_001640 N-acylaminoacyl-peptide hydrolase
13	201376_s_at	Hs.808	3185	AI591354	NM_004966 heterogeneous nuclear ribonucleoprotein F
14	201516_at	Hs.76244	6723	NM_003132.1	NM_003132 spermidine synthase
15	201600_at	Hs.7771	11331	NM_007273.1	NM_007273 B-cell associated protein
16	201625_s_at	Hs.56205	3638	BE300521	NM_005542 insulin induced gene 1
17	201797_s_at	Hs.159637	7407	NM_006295.1	NM_006295 valyl-tRNA synthetase 2
18	202115_s_at	Hs.134200	26155	NM_015658.1	NM_015658 DKFZP564C186 protein
19	202147_s_at	Hs.7879	3475	NM_001550.1	NM_001550 interferon-related developmental regulator 1
20	202159_at	Hs.23111	2193	NM_004461.1	NM_004461 phenylalanine-tRNA synthetase-like protein
21	202462_s_at	Hs.17585	9879	NM_014829.1	NM_014829 RNA helicase KIAA0801 NM_016130
22	203119_at	Hs.4253	79080	NM_024098.1	NM_024098 hypothetical protein MGC2574
23	203782_s_at	Hs.153880	5442	NM_005035.1	NM_005035 mitochondrial DNA-directed RNA polymerase precursor
24	204004_at	Hs.176090	5074	AI336206	NM_002583 apoptosis response protein
25	206158_s_at	Hs.2110	7555	NM_003418.1	NM_003418 zinc finger protein 9
26	206424_at	Hs.150595	1592	NM_000783.1	NM_000783 cytochrome P450, subfamily XXVIA, polypeptide 1, isoform 1 NM_057157

					cytochrome P450, subfamily XXVIA, polypeptide 1, isoform 2
27	206445_s_at	Hs.20521	3276	NM_001536.1	NM_001536 HMT1 hnRNP methyltransferase-like 2
28	207001_x_at	Hs.75450	1831	NM_004089.1	NM_004089 delta sleep inducing peptide, immunoreactor
29	207397_s_at	Hs.158309	3239	NM_000523.1	NM_000523 homeo box D13
30	207793_s_at	Hs.37427	2035	NM_004437.1	NM_004437 erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked)
31	208152_s_at	Hs.169531	9188	NM_004728.1	NM_004728 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 21
32	208625_s_at	Hs.211568	1981	AF104913.1	NM_004953 eukaryotic translation initiation factor 4 gamma, 1
33	208763_s_at	Hs.75450	1831	AL110191.1	NM_004089 delta sleep inducing peptide, immunoreactor
34	208910_s_at	Hs.78614	708	L04636.1	NM_001212 complement component 1, q subcomponent binding protein precursor
35	208916_at	Hs.183556	6510	AF105230.1	NM_005628 solute carrier family 1 (neutral amino acid transporter), member 5
36	208920_at	Hs.300741	6717	AV752215	NM_003130 sorcin
37	209218_at	Hs.71465	6713	AF098865.1	NM_003129 squalene monooxygenase
38	210005_at	Hs.82285	2618	D32051.1	NM_000819 phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetas
39	210337_s_at	Hs.174140	47	U18197.1	NM_001096 ATP citrate lyase
40	210347_s_at	Hs.130881	53335	AF080216.1	NM_018014 B-cell CLL/lymphoma 11A, isoform 2 NM_022893 B-cell CLL/lymphoma 11A, isoform 1 NM_138552 B-cell CLL/lymphoma 11A, isoform 4 NM_138553 B-cell CLL/lymphoma 11A, isoform 5 NM_138559 B-cell CLL/lymphoma 11A, isoform 3
41	211615_s_at	Hs.182490	10128	M92439.1	NM_133259 leucine-rich PPR-motif containing
42	211708_s_at	Hs.119597	6319	BC005807.1	NM_005063 stearoyl-CoA desaturase (delta-9-desaturase)
43	211929_at	Hs.249247	10151	BE867771	NM_005758 heterogeneous nuclear ribonucleoprotein A3
44	212009_s_at	Hs.75612	10963	BF974063	NM_006819 stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein)
45	212018_s_at			AK025446.1	
46	212174_at	Hs.171811	204	AK023758.1	NM_001625 adenylylate kinase 2 isoform a NM_013411 adenylylate kinase 2 isoform b
47	212680_x_at	Hs.100623	26472	BE305165	NM_138689 phospholipase C, beta 3, neighbor
48	213147_at	Hs.110637	3206	NM_018951.1	NM_018951 homeo box A10
49	213427_at	Hs.115823	10799	NM_006638.1	NM_006638 ribonuclease P,

					40kD subunit
50	213581_at	Hs.351862		BF446180	
51	213664_at	Hs.91139	6505	AW235061	NM_004170 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter
52	213892_s_at	Hs.28914	353	AA927724	NM_000485 adenine phosphoribosyltransferase
53	214661_s_at	Hs.117487	8602	R06783	
54	216212_s_at			AJ010395	
55	216397_s_at			AK024840.1	
56	217027_x_at			AC004941	
57	217408_at			AL050361.1	
58	217985_s_at	Hs.8858	11177	AA102574	NM_013448 bromodomain adjacent to zinc finger domain, 1A
59	218081_at	Hs.274422	54976	NM_017874.1	NM_017874 hypothetical protein FLJ20550
60	218105_s_at	Hs.279652	51073	NM_015956.1	NM_015956 mitochondrial ribosomal protein L4
61	218112_at	Hs.157160	65993	NM_023936.1	NM_023936 mitochondrial ribosomal protein S34
62	218188_s_at	Hs.23410	26517	NM_012458.1	NM_012458 translocase of inner mitochondrial membrane 13-homolog
63	218305_at	Hs.61790	79711	NM_024658.1	NM_024658 importin 4
64	218493_at	Hs.15277	79622	NM_024571.1	NM_024571 hypothetical protein FLJ22940
65	218680_x_at	Hs.300954	25764	NM_016400.1	NM_016400 Huntington interacting protein K
66	218889_at	Hs.74899	64318	NM_022451.1	NM_022451 AD24 protein
67	218893_at	Hs.103833	79763	NM_024710.1	NM_024710 hypothetical protein FLJ23469
68	219433_at	Hs.130732	54880	NM_017745.1	NM_017745 BCL-6 interacting corepressor, isoform 1 NM_020926 BCL-6 interacting corepressor, isoform 2
69	221691_x_at	Hs.9614	4869	AB042278.1	NM_002520 nucleophosmin (nucleolar phosphoprotein B23, numatrin)

SEQUENCE LISTING

<110> Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research

5

<120> Method for Detecting Teneurin Signalling and Method of Screening for Agents Involved in Teneurin Signalling

<130> 1-XXXXXP1/FMI

<160> 9

<170> PatentIn version 3.1

15 <210> 1

<211> 963

<212> DNA

<213> homo_sapiens

20 1230

221

<222> CDS

222

25 <100> 1

atg gag caa act gac tgc aaa ccc tac cag cct cta cca aaa gtc aag
Met Glu Gln Thr Asp Cys Lys Pro Tyr Gln Pro Leu Pro Lys Val Lys
1 5 10 15

48

30

cat gaa atg gat cta gct tac acc agt tct tct gat gag agt gaa gat
His Glu Met Asp Leu Ala Tyr Thr Ser Ser Ser Asp Glu Ser Glu Asp
20 25 30

96

35

gga aga aaa cca aga cag tca tac aac tcc agg gag acc ctg cac gag
Gly Arg Lys Pro Arg Gln Ser Tyr Asn Ser Arg Glu Thr Leu His Glu
35 40 45

144

40

tat aac cag gag ctg agg atg aat tac aat agc cag agt aga aag agg
 Tyr Asn Gln Glu Leu Arg Met Asn Tyr Asn Ser Gln Ser Arg Lys Arg
 50 55 60

192

45

aaa gaa gta gaa aaa tct act caa gag atg gaa ttc tgt gaa acc tct
Lys Glu Val Glu Lys Ser Thr Gln Glu Met Glu Phe Cys Glu Thr Ser
65 70 75 80

240

cac act ctg tgc tct ggc tac caa aca gac atg cac agc gtt tct cgg

288

	His Thr Leu Cys Ser Gly Tyr Gln Thr Asp Met His Ser Val Ser Arg			
	85	90	95	
	cat ggc tac cag cta gag atg gga tct gat gtg gac aca gag aca gaa		336	
5	His Gly Tyr Gln Leu Glu Met Gly Ser Asp Val Asp Thr Glu Thr Glu			
	100	105	110	
	ggt gct gcc tca cct gac cat gca cta aga atg tgg ata agg gga atg		384	
	Gly Ala Ala Ser Pro Asp His Ala Leu Arg Met Trp Ile Arg Gly Met			
10	115	120	125	
	aaa tca gag cat agt tcc tgt ttg tcc agc cgg gcc aac tct gca tta		432	
	Lys Ser Glu His Ser Ser Cys Leu Ser Ser Arg Ala Asn Ser Ala Leu			
	130	135	140	
15	tcc ttg act gac act gac cat gaa agg aag tct gat ggg gaa aat gat		480	
	Ser Leu Thr Asp Thr Asp His Glu Arg Lys Ser Asp Gly Glu Asn Asp			
	145	150	155	160
20	gtg cag agc agc cca cac aac cag ttc acc ttc aga ccc ctc cca ccg		528	
	Val Gln Ser Ser Pro His Asn Gln Phe Thr Phe Arg Pro Leu Pro Pro			
	165	170	175	
25	cca cct ccg cct cct cat gcc tgc acc tgt gcc agg aag cca ccc cct		576	
	Pro Pro Pro Pro Pro His Ala Cys Thr Cys Ala Arg Lys Pro Pro Pro			
	180	185	190	
	gca gcg gac tct ctt cag agg aga tca atg act acc cgc agc cag ccc		624	
	Ala Ala Asp Ser Leu Gln Arg Arg Ser Met Thr Thr Arg Ser Gln Pro			
30	195	200	205	
	agc cca gct gct cca gct ccc cca acc agc acg cag gat tca gtc cat		672	
	Ser Pro Ala Ala Pro Ala Pro Pro Thr Ser Thr Gln Asp Ser Val His			
	210	215	220	
35	ctg cat aac agc tgg gtc ctg aac agc aac ata cca ttg gag acc agg		720	
	Leu His Asn Ser Trp Val Leu Asn Ser Asn Ile Pro Leu Glu Thr Arg			
	225	230	235	240
40	cat ttc ctg ttc aaa cat gga tct ggt tcc tct gcg atc ttc agt gca		768	
	His Phe Leu Phe Lys His Gly Ser Gly Ser Ser Ala Ile Phe Ser Ala			
	245	250	255	
	gcc agt cag aac tac cct ctg aca tcc aat acc gtg tac tcg ccc cct		816	
45	Ala Ser Gln Asn Tyr Pro Leu Thr Ser Asn Thr Val Tyr Ser Pro Pro			
	260	265	270	

CCC agg cct ctt cct cga agc acc ttt tcc cga cct gcc ttt acc ttt
 Pro Arg Pro Leu Pro Arg Ser Thr Phe Ser Arg Pro Ala Phe Thr Phe 864
 275 280 285

5
 aac aaa cct tac agg tgc tgc aac tgg aag tgc aca gca ttg agc gcc 912
 Asn Lys Pro Tyr Arg Cys Cys Asn Trp Lys Cys Thr Ala Leu Ser Ala
 290 295 300

10 act gca atc aca gtg act ttg gcc ttg tta cta gcc tat gtg att gca 960
 Thr Ala Ile Thr Val Thr Leu Ala Leu Leu Ala Tyr Val Ile Ala
 305 310 315 320

gtg
 15 val 963

<210> 2
 <211> 321
 <212> PRT
 20 <213> homo sapiens

<400> 2

Met Glu Gln Thr Asp Cys Lys Pro Tyr Gln Pro Leu Pro Lys Val Lys
 25 1 5 10 15

His Glu Met Asp Leu Ala Tyr Thr Ser Ser Ser Asp Glu Ser Glu Asp
 20 25 30

30 Gly Arg Lys Pro Arg Gln Ser Tyr Asn Ser Arg Glu Thr Leu His Glu
 35 40 45

Tyr Asn Gln Glu Leu Arg Met Asn Tyr Asn Ser Gln Ser Arg Lys Arg
 50 55 60

35 Lys Glu Val Glu Lys Ser Thr Gln Glu Met Glu Phe Cys Glu Thr Ser
 65 70 75 80

His Thr Leu Cys Ser Gly Tyr Gln Thr Asp Met His Ser Val Ser Arg
 40 85 90 95

His Gly Tyr Gln Leu Glu Met Gly Ser Asp Val Asp Thr Glu Thr Glu
 100 105 110

45 Gly Ala Ala Ser Pro Asp His Ala Leu Arg Met Trp Ile Arg Gly Met
 115 120 125

Lys Ser Glu His Ser Ser Cys Leu Ser Ser Arg Ala Asn Ser Ala Leu
 130 135 140

5 Ser Leu Thr Asp Thr Asp His Glu Arg Lys Ser Asp Gly Glu Asn Asp
 145 150 155 160

Val Gln Ser Ser Pro His Asn Gln Phe Thr Phe Arg Pro Leu Pro Pro
 165 170 175

10 Pro Pro Pro Pro His Ala Cys Thr Cys Ala Arg Lys Pro Pro Pro
 180 185 190

Ala Ala Asp Ser Leu Gln Arg Arg Ser Met Thr Thr Arg Ser Gln Pro
 15 195 200 205

Ser Pro Ala Ala Pro Ala Pro Pro Thr Ser Thr Gln Asp Ser Val His
 210 215 220

20 Leu His Asn Ser Trp Val Leu Asn Ser Asn Ile Pro Leu Glu Thr Arg
 225 230 235 240

His Phe Leu Phe Lys His Gly Ser Gly Ser Ser Ala Ile Phe Ser Ala
 245 250 255

25 Ala Ser Gln Asn Tyr Pro Leu Thr Ser Asn Thr Val Tyr Ser Pro Pro
 260 265 270

Pro Arg Pro Leu Pro Arg Ser Thr Phe Ser Arg Pro Ala Phe Thr Phe
 30 275 280 285

Asn Lys Pro Tyr Arg Cys Cys Asn Trp Lys Cys Thr Ala Leu Ser Ala
 290 295 300

35 Thr Ala Ile Thr Val Thr Leu Ala Leu Leu Leu Ala Tyr Val Ile Ala
 305 310 315 320

Val

40 <210> 3
 <211> 1194
 <212> DNA
 <213> homo sapiens

45

<220>

<221> CDS

<222> (1)..(1194)

<223>

5

<400> 3

atg gat gta aag gac cg_g cga c_ac cgc tct ttg acc aga gga cgc tgt
 Met Asp Val Lys Asp Arg Arg His Arg Ser Leu Thr Arg Gly Arg Cys 48
 1 5 10 15

10

ggc aaa gag tgt cgc tac aca agc tcc tct ctg gac agt gag gac tgc
 Gly Lys Glu Cys Arg Tyr Thr Ser Ser Leu Asp Ser Glu Asp Cys 96
 20 25 30

15

cgc gtg ccc aca cag aaa tcc tac agc tcc agt gag act ctg aag gcc
 Arg Val Pro Thr Gln Lys Ser Tyr Ser Ser Glu Thr Leu Lys Ala 144
 35 40 45

20

tat gac cat gac agc agg atg cac tat gga aac cga gtc aca gac ctc
 Tyr Asp His Asp Ser Arg Met His Tyr Gly Asn Arg Val Thr Asp Leu 192
 50 55 60

atc cac cgg gag tca gat gag ttt cct aga caa gga acc aac ttc acc 240
 Ile His Arg Glu Ser Asp Glu Phe Pro Arg Gln Gly Thr Asn Phe Thr

25 65 70 75 80

ctt gcc gaa ctg ggc atc tgt gag ccc tcc cca cac cga agc ggc tac
 Leu Ala Glu Leu Gly Ile Cys Glu Pro Ser Pro His Arg Ser Gly Tyr 288
 85 90 95

30

tgc tcc gac atg ggg atc ctt cac cag ggc tac tcc ctt agc aca ggg
 Cys Ser Asp Met Gly Ile Leu His Gln Gly Tyr Ser Leu Ser Thr Gly 336
 100 105 110

35 tct gac gcc gac tcc gac acc gag gga ggg atg tct cca gaa cac gcc
 Ser Asp Ala Asp Ser Asp Thr Glu Gly Gly Met Ser Pro Glu His Ala 384
 115 120 125

40 atc aga ctg tgg ggc aga ggg ata aaa tcc agg cgc agt tcc ggc ctg
 Ile Arg Leu Trp Gly Arg Gly Ile Lys Ser Arg Arg Ser Ser Gly Leu 432
 130 135 140

45 tcc agt cgt gaa aac tcg gcc ctt acc ctg act gac tct gac aac gaa
 Ser Ser Arg Glu Asn Ser Ala Leu Thr Leu Thr Asp Ser Asp Asn Glu 480
 145 150 155 160

aac aaa tca gat gat gag aac gaa agt cgt ccc att cca cct aca tcc Asn Lys Ser Asp Asp Glu Asn Glu Ser Arg Pro Ile Pro Pro Thr Ser 165 170 175	528
5 tcg cct agt ctc ctc cca tct gct cag ctg cct agc tcc cat aat cct Ser Pro Ser Leu Leu Pro Ser Ala Gln Leu Pro Ser Ser His Asn Pro 180 185 190	576
10 cca cca gtt agc tgc cag atg cca ttg cta gac agc aac acc tcc cat Pro Pro Val Ser Cys Gln Met Pro Leu Leu Asp Ser Asn Thr Ser His 195 200 205	624
15 caa atc atg gac acc aac cct gat gag gaa ttc tcc ccc aat tca tac Gln Ile Met Asp Thr Asn Pro Asp Glu Glu Phe Ser Pro Asn Ser Tyr 210 215 220	672
20 ctg ctc aga gca tgc tca ggg ccc cag caa gcc tcc agc agt ggc cct Leu Leu Arg Ala Cys Ser Gly Pro Gln Gln Ala Ser Ser Ser Gly Pro 225 230 235 240	720
25 ccg aac cac cac agc cag tcg act ctg agg ccc cct ctc cca ccc cct Pro Asn His His Ser Gln Ser Thr Leu Arg Pro Pro Leu Pro Pro Pro 245 250 255	768
30 cac aac cac acg ctg tcc cat cac cac tcg tcc gcc aac tcc ctc aac His Asn His Thr Leu Ser His His Ser Ser Ala Asn Ser Leu Asn 260 265 270	816
35 agg aac tca ctg acc aat cgg cgg agt cag atc cac gcc ccc gcc cca Arg Asn Ser Leu Thr Asn Arg Arg Ser Gln Ile His Ala Pro Ala Pro 275 280 285	864
40 gcg ccc aat gac ctg gcc acc aca cca gag tcc gtt cag ctt cag gac Ala Pro Asn Asp Leu Ala Thr Thr Pro Glu Ser Val Gln Leu Gln Asp 290 295 300	912
45 agc tgg gtg cta aac agc aac gtg cca ctg gag acc cgg cac ttc ctc Ser Trp Val Leu Asn Ser Asn Val Pro Leu Glu Thr Arg His Phe Leu 305 310 315 320	960
50 ttc aag acc tcc tcg ggg agc aca ccc ttg ttc agc agc tct tcc ccg Phe Lys Thr Ser Ser Gly Ser Thr Pro Leu Phe Ser Ser Ser Pro 325 330 335	1008
55 gga tac cct ttg acc tca gga acg gtt tac acg ccc ccg ccc cgc ctg Gly Tyr Pro Leu Thr Ser Gly Thr Val Tyr Thr Pro Pro Pro Arg Leu	1056

340

345

350

ctg ccc agg aat act ttc tcc agg aag gct ttc aag ctg aag aag ccc
 Leu Pro Arg Asn Thr Phe Ser Arg Lys Ala Phe Lys Leu Lys Lys Pro 1104
 5 355 360 365

tcc aaa tac tgc aac tgg aaa tgt gct gcc ctc tcc gcc att gcc gcg
 Ser Lys Tyr Cys Ser Trp Lys Cys Ala Ala Leu Ser Ala Ile Ala Ala 1152
 10 370 375 380

gcc ctc ctc ttg gct att ttg ctg gcg tat ttc ata gca atg
 Ala Leu Leu Leu Ala Ile Leu Leu Ala Tyr Phe Ile Ala Met 1194
 385 390 395

15

<210> 4
 <211> 398
 <212> PRT
 <213> homo sapiens

20

<400> 4

Met Asp Val Lys Asp Arg Arg His Arg Ser Leu Thr Arg Gly Arg Cys
 1 5 10 15

25

Gly Lys Glu Cys Arg Tyr Thr Ser Ser Ser Leu Asp Ser Glu Asp Cys
 20 25 30

30

Arg Val Pro Thr Gln Lys Ser Tyr Ser Ser Ser Glu Thr Leu Lys Ala
 35 40 45

Tyr Asp His Asp Ser Arg Met His Tyr Gly Asn Arg Val Thr Asp Leu
 50 55 60

35

Ile His Arg Glu Ser Asp Glu Phe Pro Arg Gln Gly Thr Asn Phe Thr
 65 70 75 80

40

Leu Ala Glu Leu Gly Ile Cys Glu Pro Ser Pro His Arg Ser Gly Tyr
 85 90 95

Cys Ser Asp Met Gly Ile Leu His Gln Gly Tyr Ser Leu Ser Thr Gly
 100 105 110

45

Ser Asp Ala Asp Ser Asp Thr Glu Gly Gly Met Ser Pro Glu His Ala
 115 120 125

Ile Arg Leu Trp Gly Arg Gly Ile Lys Ser Arg Arg Ser Ser Gly Leu
 130 135 140

5 Ser Ser Arg Glu Asn Ser Ala Leu Thr Leu Thr Asp Ser Asp Asn Glu
 145 150 155 160

Asn Lys Ser Asp Asp Glu Asn Glu Ser Arg Pro Ile Pro Pro Thr Ser
 165 170 175

10 Ser Pro Ser Leu Leu Pro Ser Ala Gln Leu Pro Ser Ser His Asn Pro
 180 185 190

Pro Pro Val Ser Cys Gln Met Pro Leu Leu Asp Ser Asn Thr Ser His
 195 200 205

Gln Ile Met Asp Thr Asn Pro Asp Glu Glu Phe Ser Pro Asn Ser Tyr
 210 215 220

20 Leu Leu Arg Ala Cys Ser Gly Pro Gln Gln Ala Ser Ser Ser Gly Pro
 225 230 235 240

Pro Asn His His Ser Gln Ser Thr Leu Arg Pro Pro Leu Pro Pro Pro
 245 250 255

25 His Asn His Thr Leu Ser His His Ser Ser Ala Asn Ser Leu Asn
 260 265 270

Arg Asn Ser Leu Thr Asn Arg Arg Ser Gln Ile His Ala Pro Ala Pro
 275 280 285

Ala Pro Asn Asp Leu Ala Thr Thr Pro Glu Ser Val Gln Leu Gln Asp
 290 295 300

35 Ser Trp Val Leu Asn Ser Asn Val Pro Leu Glu Thr Arg His Phe Leu
 305 310 315 320

Phe Lys Thr Ser Ser Gly Ser Thr Pro Leu Phe Ser Ser Ser Pro
 325 330 335

40 Gly Tyr Pro Leu Thr Ser Gly Thr Val Tyr Thr Pro Pro Pro Arg Leu
 340 345 350

45 Leu Pro Arg Asn Thr Phe Ser Arg Lys Ala Phe Lys Leu Lys Lys Pro
 355 360 365

Ser Lys Tyr Cys Ser Trp Lys Cys Ala Ala Leu Ser Ala Ile Ala Ala
 370 375 380
 5 Ala Leu Leu Leu Ala Ile Leu Leu Ala Tyr Phe Ile Ala Met
 385 390 395

10 <210> 5
 <211> 993
 <212> DNA
 <213> homo sapiens

15 <220>
 <221> CDS
 <222> (1)..(993)
 <223>

20 <400> 5
 atg gat gtg aaa gaa cgc agg cct tac tgc tcc ctg acc aag agc aga 48
 Met Asp Val Lys Glu Arg Arg Pro Tyr Cys Ser Leu Thr Lys Ser Arg
 1 5 10 15

25 cga gag aag gaa cgg cgc tac aca aat tcc tcc gca gac aat gag gag 96
 Arg Glu Lys Glu Arg Arg Tyr Thr Asn Ser Ser Ala Asp Asn Glu Glu
 20 25 30

30 tgc cgg gta ccc aca cag aag tcc tac agt tcc agc gag aca ttg aaa 144
 Cys Arg Val Pro Thr Gln Lys Ser Tyr Ser Ser Glu Thr Leu Lys
 35 40 45

35 gct ttt gat cat gat tcc tcg cgg ctg ctt tac ggc aac aga gtg aag 192
 Ala Phe Asp His Asp Ser Ser Arg Leu Leu Tyr Gly Asn Arg Val Lys
 50 55 60

40 gat ttg gtt cac aga gaa gca gac gag ttc act aga caa gga cag aat 240
 Asp Leu Val His Arg Glu Ala Asp Glu Phe Thr Arg Gln Gln Asn
 65 70 75 80

45 ttt acc cta agg cag tta gga gtt tgt gaa cca gca act cga aga gga 288
 Phe Thr Leu Arg Gln Leu Gly Val Cys Glu Pro Ala Thr Arg Arg Gly
 85 90 95

ctg gca ttt tgt gcg gaa atg ggg ctc cct cac aga ggt tac tct atc
 45 Leu Ala Phe Cys Ala Glu Met Gly Leu Pro His Arg Gly Tyr Ser Ile 336
 100 105 110

	agt gca ggg tca gat gct gat act gaa aat gaa gca gtg atg tcc cca	384
	Ser Ala Gly Ser Asp Ala Asp Thr Glu Asn Glu Ala Val Met Ser Pro	
	115 120 125	
5		
	gag cat gcc atg aga ctt tgg ggc agg ggg gtc aaa tca ggc cgc agc	432
	Glu His Ala Met Arg Leu Trp Gly Arg Gly Val Lys Ser Gly Arg Ser	
	130 135 140	
10	tcc tgc ctg tca agt cgg tcc aac tca gcc ctc acc ctg aca gat acg	480
	Ser Cys Leu Ser Ser Arg Ser Asn Ser Ala Leu Thr Leu Thr Asp Thr	
	145 150 155 160	
15	gag cac gaa aac aag tcc gac agt gag aat gag caa cct gca agc aat	528
	Glu His Glu Asn Lys Ser Asp Ser Glu Asn Glu Gln Pro Ala Ser Asn	
	165 170 175	
20	caa ggc cag tct acc ctg cag ccc ttg ccg cct tcc cat aag cag cac	576
	Gln Gln Ser Thr Leu Gln Pro Leu Pro Pro Ser His Lys Gln His	
	180 185 190	
25	tct gca cag cat cat cca tcc atc act tct ctc aac aga aac tcc ctg	624
	Ser Ala Gln His His Pro Ser Ile Thr Ser Leu Asn Arg Asn Ser Leu	
	195 200 205	
30	acc aat aga agg aac cag agt ccg gcc ccg gct gct ttg ccc gcc	672
	Thr Asn Arg Arg Asn Gln Ser Pro Ala Pro Pro Ala Ala Leu Pro Ala	
	210 215 220	
35	gag ctg caa acc aca ccc gag tcc gtc cag ctg cag gac agc tgg gtc	720
	Glu Leu Gln Thr Thr Pro Glu Ser Val Gln Leu Gln Asp Ser Trp Val	
	225 230 235 240	
40	ctt ggc agt aat gta cca ctg gaa agc agg cat ttc cta ttc aaa aca	768
	Leu Gly Ser Asn Val Pro Leu Glu Ser Arg His Phe Leu Phe Lys Thr	
	245 250 255	
45	gga aca ggt aca acg cca ctg ttc agt act gca acc cca gga tac aca	816
	Gly Thr Gly Thr Pro Leu Phe Ser Thr Ala Thr Pro Gly Tyr Thr	
	260 265 270	
	atg gca tct ggc tct gtt tat tca cca cct act cgg cca cta cct aga	864
	Met Ala Ser Gly Ser Val Tyr Ser Pro Pro Thr Arg Pro Leu Pro Arg	
	275 280 285	
	aac acc cta tca aga agt gct ttt aaa ttc aag aag tct tca aag tac	912

Asn Thr Leu Ser Arg Ser Ala Phe Lys Phe Lys Lys Ser Ser Lys Tyr
 290 295 300

tgt agc tgg aaa tgc act gca ctg tgt gcc gta ggg gtc tcg gtg ctc
 5 Cys Ser Trp Lys Cys Thr Ala Leu Cys Ala Val Gly Val Ser Val Leu
 305 310 315 320

ctg gca ata ctc ctg tct tat ttt ata gca atg
 Leu Ala Ile Leu Leu Ser Tyr Phe Ile Ala Met
 10 325 330

<210> 6
 <211> 331
 15 <212> PRT
 <213> homo sapiens

<400> 6

20 Met Asp Val Lys Glu Arg Arg Pro Tyr Cys Ser Leu Thr Lys Ser Arg
 1 5 10 15

Arg Glu Lys Glu Arg Arg Tyr Thr Asn Ser Ser Ala Asp Asn Glu Glu
 25 20 25 30

Cys Arg Val Pro Thr Gln Lys Ser Tyr Ser Ser Ser Glu Thr Leu Lys
 35 35 40 45

Ala Phe Asp His Asp Ser Ser Arg Leu Leu Tyr Gly Asn Arg Val Lys
 30 50 55 60

Asp Leu Val His Arg Glu Ala Asp Glu Phe Thr Arg Gln Gly Gln Asn
 65 65 70 75 80

35 Phe Thr Leu Arg Gln Leu Gly Val Cys Glu Pro Ala Thr Arg Arg Gly
 85 85 90 95

Leu Ala Phe Cys Ala Glu Met Gly Leu Pro His Arg Gly Tyr Ser Ile
 40 100 105 110

Ser Ala Gly Ser Asp Ala Asp Thr Glu Asn Glu Ala Val Met Ser Pro
 115 115 120 125

45 Glu His Ala Met Arg Leu Trp Gly Arg Gly Val Lys Ser Gly Arg Ser
 130 135 140

Ser Cys Leu Ser Ser Arg Ser Asn Ser Ala Leu Thr Leu Thr Asp Thr
 145 150 155 160

Glu His Glu Asn Lys Ser Asp Ser Glu Asn Glu Gln Pro Ala Ser Asn
 5 165 170 175

Gln Gly Gln Ser Thr Leu Glu Pro Leu Pro Pro Ser His Lys Gln His
 180 185 190

10 Ser Ala Gln His His Pro Ser Ile Thr Ser Leu Asn Arg Asn Ser Leu
 195 200 205

Thr Asn Arg Arg Asn Gln Ser Pro Ala Pro Pro Ala Ala Leu Pro Ala
 210 215 220

15 Glu Leu Gln Thr Thr Pro Glu Ser Val Gln Leu Gln Asp Ser Trp Val
 225 230 235 240

Leu Gly Ser Asn Val Pro Leu Glu Ser Arg His Phe Leu Phe Lys Thr
 20 245 250 255

Gly Thr Gly Thr Thr Pro Leu Phe Ser Thr Ala Thr Pro Gly Tyr Thr
 260 265 270

25 Met Ala Ser Gly Ser Val Tyr Ser Pro Pro Thr Arg Pro Leu Pro Arg
 275 280 285

Asn Thr Leu Ser Arg Ser Ala Phe Lys Phe Lys Lys Ser Ser Lys Tyr
 290 295 300

30 Cys Ser Trp Lys Cys Thr Ala Leu Cys Ala Val Gly Val Ser Val Leu
 305 310 315 320

Leu Ala Ile Leu Leu Ser Tyr Phe Ile Ala Met
 35 325 330

<210> 7
 <211> 1089

40 <212> DNA
 <213> homo sapiens

<220>
 <221> CDS

45 <222> (1)..(1089)
 <223>

<400> 7

5	atg gac gtg aag gag agg aag cct tac cgc tcg ctg acc cgg cgc cgc Met Asp Val Lys Glu Arg Lys Pro Tyr Arg Ser Leu Thr Arg Arg Arg 1 5 10 15	48
10	gac gcc gag cgc cgc tac acc agc tcg tcc gcg gac agc gag gag ggc Asp Ala Glu Arg Arg Tyr Thr Ser Ser Ala Asp Ser Glu Glu Gly 20 25 30	96
15	aaa gcc ccg cag aaa tcg tac agc tcc agc gag acc ctg aag gcc tac Lys Ala Pro Gln Lys Ser Tyr Ser Ser Glu Thr Leu Lys Ala Tyr 35 40 45	144
20	gac cag gag gcc cgc cta gcc tat ggc agc cgc gtc aag gac att gtg Asp Gln Asp Ala Arg Leu Ala Tyr Gly Ser Arg Val Lys Asp Ile Val 50 55 60	192
25	ccg cag gag gcc gag gaa ttc tgc cgc aca ggt gcc aac ttc acc ctg Pro Gln Glu Ala Glu Glu Phe Cys Arg Thr Gly Ala Asn Phe Thr Leu 65 70 75 80	240
30	cgg gag ctg ggg ctg gaa gaa gta acg ccc cct cac ggg acc ctg tac Arg Glu Leu Gly Leu Glu Glu Val Thr Pro Pro His Gly Thr Leu Tyr 85 90 95	288
35	cgg aca gac att ggc ctc ccc cac tgc ggc tac tcc atg ggg gct ggc Arg Thr Asp Ile Gly Leu Pro His Cys Gly Tyr Ser Met Gly Ala Gly 100 105 110	336
40	tct gat gcc gac atg gag gct gac acg gtg ctg tcc cct gag cac ccc Ser Asp Ala Asp Met Glu Ala Asp Thr Val Leu Ser Pro Glu His Pro 115 120 125	384
45	gtg cgt ctg tgg ggc cgg agc aca cgg tca ggg cgc agc tcc tgc ctg Val Arg Leu Trp Gly Arg Ser Thr Arg Ser Gly Arg Ser Ser Cys Leu 130 135 140	432
	tcc agc cgg gcc aat tcc aat ctc aca ctc acc gac acc gag cat gaa Ser Ser Arg Ala Asn Ser Asn Leu Thr Leu Thr Asp Thr Glu His Glu 145 150 155 160	480
	aac act gag act gat cat ccg ggc ggc ctg cag aac cac gcg cgg ctc Asn Thr Glu Thr Asp His Pro Gly Gly Leu Gln Asn His Ala Arg Leu 165 170 175	528

	cgg acg ccg ccg ccg ctc tcg cac gcc cac acc ccc aac cag cac		576
Arg Thr Pro Pro Pro Pro Leu Ser His Ala His Thr Pro Asn Gln His			
180	185	190	
5	cac gcg gcc tcc att aac tcc ctg aac cg ^g ggc aac ttc acg ccg agg		624
His Ala Ala Ser Ile Asn Ser Leu Asn Arg Gly Asn Phe Thr Pro Arg			
195	200	205	
10	agc aac ccc agc ccg gcc ccc acg gac cac tcg ctc tcc gga gag ccc		672
Ser Asn Pro Ser Pro Ala Pro Thr Asp His Ser Leu Ser Gly Glu Pro			
210	215	220	
15	cct gcc ggc ggc gcc cag gag cct gcc cac gcc cag gag aac tgg ctg		720
Pro Ala Gly Gly Ala Gln Glu Pro Ala His Ala Gln Glu Asn Trp Leu			
225	230	235	240
20	ctc aac agc aac atc ccc ctg gag acc aga aac cta ggc aag cag cca		768
Leu Asn Ser Asn Ile Pro Leu Glu Thr Arg Asn Leu Gly Lys Gln Pro			
245	250	255	
25	ttc cta ggg aca ttg cag gac aac ctc att gag atg gac att ctc ggc		816
Phe Leu Gly Thr Leu Gln Asp Asn Leu Ile Glu Met Asp Ile Leu Gly			
260	265	270	
30	gcc tcc cgc cat gat ggg gct tac agt gac ggg cac ttc ctc ttc aag		864
Ala Ser Arg His Asp Gly Ala Tyr Ser Asp Gly His Phe Leu Phe Lys			
275	280	285	
35	cct gga ggc acc tcc ccg ctc ttc tgc acc aca tca cca ggg tac cca		912
Pro Gly Gly Thr Ser Pro Leu Phe Cys Thr Thr Ser Pro Gly Tyr Pro			
290	295	300	
40	ctg acg tcc agc aca gtg tac tct cct ccg ccc cga ccc ctg ccc cgc		960
Leu Thr Ser Ser Thr Val Tyr Ser Pro Pro Pro Arg Pro Leu Pro Arg			
305	310	315	320
45	agc acc ttc gcc ccg ccg ttt aac ctc aag aag ccc tcc aag tac		1008
Ser Thr Phe Ala Arg Pro Ala Phe Asn Leu Lys Lys Pro Ser Lys Tyr			
325	330	335	
tgt aac tgg aag tgc gca gcc ctg agc gcc atc gtc atc tca gcc act			1056
Cys Asn Trp Lys Cys Ala Ala Leu Ser Ala Ile Val Ile Ser Ala Thr			
340	345	350	
45	ctg gtc atc ctg ctg gca tac ttt gtg gcc atg		1089

Leu Val Ile Leu Leu Ala Tyr Phe Val Ala Met
 355 360

5 <210> 8
 <211> 363
 <212> PRT
 <213> homo sapiens

10 <400> 8

Met Asp Val Lys Glu Arg Lys Pro Tyr Arg Ser Leu Thr Arg Arg Arg
 1 5 10 15

15 Asp Ala Glu Arg Arg Tyr Thr Ser Ser Ala Asp Ser Glu Glu Gly
 20 25 30

Lys Ala Pro Gln Lys Ser Tyr Ser Ser Glu Thr Leu Lys Ala Tyr
 35 40 45
 20

Asp Gln Asp Ala Arg Leu Ala Tyr Gly Ser Arg Val Lys Asp Ile Val
 50 55 60

25 Pro Gln Glu Ala Glu Glu Phe Cys Arg Thr Gly Ala Asn Phe Thr Leu
 65 70 75 80

Arg Glu Leu Gly Leu Glu Glu Val Thr Pro Pro His Gly Thr Leu Tyr
 85 90 95

30 Arg Thr Asp Ile Gly Leu Pro His Cys Gly Tyr Ser Met Gly Ala Gly
 100 105 110

35 Ser Asp Ala Asp Met Glu Ala Asp Thr Val Leu Ser Pro Glu His Pro
 115 120 125

Val Arg Leu Trp Gly Arg Ser Thr Arg Ser Gly Arg Ser Ser Cys Leu
 130 135 140

40 Ser Ser Arg Ala Asn Ser Asn Leu Thr Leu Thr Asp Thr Glu His Glu
 145 150 155 160

45 Asn Thr Glu Thr Asp His Pro Gly Gly Leu Gln Asn His Ala Arg Leu
 165 170 175

Arg Thr Pro Pro Pro Pro Leu Ser His Ala His Thr Pro Asn Gln His

180

185

190

His Ala Ala Ser Ile Asn Ser Leu Asn Arg Gly Asn Phe Thr Pro Arg
 195 200 205

5 Ser Asn Pro Ser Pro Ala Pro Thr Asp His Ser-Leu-Ser Gly Glu-Pro
 210 215 220

Pro Ala Gly Gly Ala Gln Glu Pro Ala His Ala Gln Glu Asn Trp Leu
 10 225 230 235 240

Leu Asn Ser Asn Ile Pro Leu Glu Thr Arg Asn Leu Gly Lys Gln Pro
 245 250 255

15 Phe Leu Gly Thr Leu Gln Asp Asn Leu Ile Glu Met Asp Ile Leu Gly
 260 265 270

Ala Ser Arg His Asp Gly Ala Tyr Ser Asp Gly His Phe Leu Phe Lys
 275 280 285

20 Pro Gly Gly Thr Ser Pro Leu Phe Cys Thr Thr Ser Pro Gly Tyr Pro
 290 295 300

Leu Thr Ser Ser Thr Val Tyr Ser Pro Pro Pro Arg Pro Leu Pro Arg
 25 305 310 315 320

Ser Thr Phe Ala Arg Pro Ala Phe Asn Leu Lys Lys Pro Ser Lys Tyr
 325 330 335

30 Cys Asn Trp Lys Cys Ala Ala Leu Ser Ala Ile Val Ile Ser Ala Thr
 340 345 350

Leu Val Ile Leu Leu Ala Tyr Phe Val Ala Met
 355 360

35

<210> 9

<211> 363

<212> PRT

40 <213> homo sapiens

<400> 9

ggccagtgaa ttgttaatacg actcactata gggaggcggt tttttttttt tttttttttt 60

45 ttt

What is claimed is:

1. A method for detecting teneurin signalling, which method comprises:
 - 5 a) determining the presence of a cleaved teneurin product associated with teneurin signalling; and
 - b) correlating the presence and/or amount of said cleaved teneurin product with teneurin signalling.
- 10 2. A method as claimed in claim 1, wherein said cleaved teneurin product is the cytoplasmic domain of teneurin.
3. A method as claimed in claim 1 or 2, wherein said teneurin is teneurin-1, teneurin-2, teneurin-3 or teneurin-4.
- 15 4. A method as claimed in any one of the preceding claims wherein the cleaved teneurin product is formed in tumour cells.
5. A method as claimed in any one of claims 1 to 3, wherein the cleaved teneurin product is formed in neurons.
- 20 6. A method as claimed in any one of the preceding claims further comprising providing a teneurin or a fragment thereof comprising at least a portion of the N-terminal domain of teneurin and at least a portion of the C-terminal domain of teneurin, and a cellular component that cleaves teneurin.
- 25 7. A method as claimed in claim 6, wherein the teneurin is recombinant.
8. A method as claimed in any one of the preceding claims wherein the cleaved teneurin product comprises a tag or label.
- 30 9. A method as claimed in claim 8, wherein said determining step (b) comprises detecting said tag or label photometrically.
- 35 10. A method as claimed in claim 8, wherein said tag is selected from the group consisting of GFP, YFP, hemagglutinin, (Histidine)₇, a DNA binding domain.

11. A method as claimed in claim 10 wherein said determining step (b) comprises allowing said DNA binding domain to bind to a nucleic acid comprising regulatory sequences operably linked to a reporter gene and detecting activity of said reporter gene.
- 5
12. A method as claimed in claim 10 wherein said DNA binding domain comprises a GAL4 DNA binding domain.
- 10
13. A method as claimed in claim 10, 11 or 12 wherein said tag is a DNA binding domain and further comprises an NF κ B domain.
14. A method as claimed in any one of the preceding claims wherein said determining step comprises determining the amount of said cleaved tenascin product.
- 15
15. A method as claimed in any one of the preceding claims, wherein the cleaved teneurin product targets to the cell nucleus.
16. A method as claimed in any one of the preceding claims wherein the cleaved teneurin product regulates expression or activity of a cellular target.
- 20
17. A method as claimed in claim 16 further comprising detecting expression or activity of said cellular target.
18. A method as claimed in claim 17 wherein said cellular target is PML.
- 25
19. A method as claimed in claim 17 wherein said cellular target is Zic.
20. A method as claimed in claim 17 wherein said cellular target is ponsin.
- 30
21. A method as claimed in claim 1, wherein the presence and/or amount of the cleaved teneurin product is correlated to a particular disease or condition.
22. A method as claimed in claim 21, wherein said disease or condition is selected from the group consisting of cell proliferation and neuronal differentiation.

23. Use of a detectable cleaved teneurin product associated with teneurin signalling in a method of diagnosis of a neuropathology or cell pathology affected by teneurin signalling.
- 5 24. A method for assessing the ability of an agent to modulate teneurin signalling, comprising the steps of:
- (a) contacting teneurin with at least one agent;
 - (b) detecting cleavage of said teneurin by a cellular component associated with teneurin signalling in the presence of said agent; and
 - (c) correlating a difference in cleavage of said teneurin relative to when said agent is absent with an indication of the presence of an agent effective in modulating teneurin signalling.
- 10 25. A method as claimed in claim 24 wherein step (a) is performed by perfusing a cell expressing teneurin with the agent.
- 15 26. A method for assessing the ability of an agent to modulate teneurin-mediated signalling, comprising the steps of:
- (a) exposing a cell to an agent;
 - (b) detecting expression or activity of a gene regulated by teneurin in said cell; and
 - (c) correlating a change in expression or activity of said gene with the presence of a modulator of teneurin signalling.
- 20 27. A method as claimed in claim 24 to 26 for screening for compounds for the treatment of a neurodegenerative disease or disorder.
- 25 28. A composition detected by a method of any one of claims 24 to 26 for the treatment or prophylactic treatment of tumourigenesis or cancer.
- 30 29. A composition detected by a method of any one of claims 24 to 26 for the treatment or prophylactic treatment of a neuropathological condition.
- 35 30. The use of a composition of claim 28 for the manufacture of a medicament for the treatment or prophylactic treatment of tumourigenesis or cancer.

31. The use of a composition of claim 29 for the manufacture of a medicament for the treatment or prophylactic treatment of a neuropathological condition.
- 5 32. The use of a cleaved teneurin product for the manufacture of a medicament for the treatment or prophylactic treatment of tumourigenesis or cancer.
- 10 33. The use of a cleaved teneurin product for the manufacture of a medicament for the treatment or prophylactic treatment of a neuropathological condition.
- 15 34. A composition comprising a cleaved teneurin product and a cellular target of the cleaved teneurin product.
35. A composition as claimed in claim 34 wherein said cellular target is PML.
- 15 36. A composition as claimed in claim 34 wherein said cellular target is Zic.
37. A composition as claimed in claim 34 wherein said cellular target is ponsin.
38. A composition as claimed in claim 34 wherein said cellular target is myc.
- 20 39. A composition as claimed in claim 34 wherein said cellular target is p53.
40. A kit comprising a teneurin and a protease.

ABSTRACT5 METHODS FOR DETECTING TENEURIN SIGNALLING AND RELATED
SCREENING METHODS

10 Methods are provided for detecting teneurin signalling by determining the presence and/or amount of a cleaved teneurin product, and correlating the presence and/or amount of the cleaved teneurin product with teneurin signalling. The methods can be used for screening possible anti-tumour agents or agents that modulate neuronal differentiation. Test substances are assayed for their ability to increase or decrease the presence of the cytoplasmic domain of teneurin or of its respective targets, such as ponsin, PML and zic.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.